On this page
Quick Reference
Overview and Recommendations
Background
- •Hyperlipidemia, elevation of LDL-C, triglycerides, or both, affects approximately 73% of US adults with hypertension and accounts for roughly half the population-attributable risk of myocardial infarction. Lifetime risk of cardiovascular disease at age 50 with all major risk factors present is 38% in men and 24% in women, underscoring the profound prognostic stakes.
- •The four pillars of guideline-directed medical therapy, high-intensity , , , and , have replaced the older statin-alone paradigm following landmark trials such as IMPROVE-IT (ezetimibe add-on), FOURIER (PCSK9i), and CLEAR-Outcomes (bempedoic acid). Combined LDL-C reduction can exceed 80% with statin plus a PCSK9 inhibitor.
- •Subendothelial retention of apolipoprotein B-containing lipoproteins (chiefly LDL and VLDL remnants) is the initiating event in atherogenesis. Oxidative modification of retained LDL triggers endothelial activation, monocyte recruitment, and foam-cell formation, the core pathophysiological cascade that progresses to plaque formation and rupture.
- •Primary (genetic) hyperlipidemia includes familial hypercholesterolemia (FH; prevalence 1:250 for heterozygotes), familial combined hyperlipidemia (1:100), and severe hypertriglyceridemia syndromes. Secondary causes, diabetes, hypothyroidism, nephrotic syndrome, cholestasis, and medications (thiazides, retinoids, protease inhibitors), must be excluded before labeling a patient with a primary disorder.
- •Untreated hyperlipidemia accelerates atherosclerotic progression: premature ASCVD (MI or stroke before age 55 in men, 60 in women) is a hallmark of FH. Primary prevention with statins reduces all-cause mortality by 14% (RR 0.86) and major cardiovascular events by approximately 30%, with consistent benefit across age and sex subgroups.
Evaluation
- •Suspect hyperlipidemia in any patient with exertional dyspnea, unexplained fatigue, or a family history of premature ASCVD, especially when combined with stigmata such as xanthomas or xanthelasma on physical exam.
- •Ask about prior lipid values, personal history of coronary artery disease, stroke, or peripheral artery disease, and any history of acute pancreatitis (marker of severe hypertriglyceridemia). Thoroughly review medications: thiazides, non-selective beta-blockers, retinoids, anabolic steroids, and protease inhibitors can all elevate lipids.
- •Examine for tendon xanthomas, palpate the Achilles tendon while the foot is dorsiflexed; nodular thickening is pathognomonic for (FH). Also check for xanthelasma palpebrarum, arcus corneae before age 45, and eruptive xanthomas (yellow papules on extensor surfaces) that indicate severe hypertriglyceridemia.
- •Order a fasting lipid panel as the gold-standard initial test: measure total cholesterol, LDL-C, HDL-C, and triglycerides. A non-fasting panel is acceptable for initial screening; if total cholesterol ≥200 mg/dL or HDL-C <40 mg/dL, repeat with fasting to confirm.
- •Assess for secondary causes of hyperlipidemia with laboratory studies: TSH (hypothyroidism), HbA1c or fasting glucose (diabetes), urine protein or albumin-creatinine ratio (nephrotic syndrome), and hepatic transaminases (cholestasis, non-alcoholic fatty liver disease).
- •Calculate 10-year ASCVD risk using the (ACC/AHA) or SCORE (ESC) for all adults aged 40-75 years without established ASCVD. Categories: low (<5%), borderline (5-7.5%), intermediate (7.5-20%), and high (≥20%).
- •When LDL-C is ≥190 mg/dL, apply the (DLCN) criteria: assign points based on LDL-C level, family history, personal ASCVD, and physical signs. A score >8 defines definite FH, while 6-8 indicates probable FH. Genetic testing for LDLR, APOB, and PCSK9 mutations is recommended for patients with DLCN score ≥6.
- •Measure [Lp(a)] once in adults; a level ≥50 mg/dL (or ≥125 nmol/L) is an independent risk-enhancing factor that warrants more intensive lipid lowering even if LDL-C appears well controlled.
- •In patients with triglycerides ≥500 mg/dL, rule out familial chylomicronemia syndrome (genetic testing for LPL, APOC2, APOA5) and consider urgent therapy to prevent pancreatitis. Also check for contributory factors such as uncontrolled diabetes, excess alcohol intake, and estrogen therapy.
- •For intermediate-risk patients (7.5-20% 10-year risk), refine risk assessment with coronary artery calcium scoring or high-sensitivity CRP (hsCRP ≥2 mg/L indicates residual inflammatory risk). A CAC score of zero can reclassify many to low risk, potentially deferring statin therapy.
Management
- •Initiate high-intensity statin therapy immediately for all patients with established ASCVD: 40-80 mg daily or 20-40 mg daily, regardless of baseline LDL-C level. For primary prevention with LDL-C ≥190 mg/dL or 10-year risk ≥20%, start a high-intensity statin as first-line.
- •Begin statin therapy at moderate intensity (atorvastatin 10-20 mg or rosuvastatin 5-10 mg) for primary prevention patients with intermediate risk (7.5-20%). Titrate every 4-12 weeks to achieve ≥50% LDL-C reduction.
- •Add 10 mg daily if LDL-C remains ≥70 mg/dL (or ≥55 mg/dL in very high risk, defined as ASCVD with major risk factors or recurrent events) after 12 weeks of maximally tolerated statin. Ezetimibe provides an additional ~15-20% LDL-C reduction.
- •For very high risk patients not at goal on statin plus ezetimibe, advance to a : 140 mg subcutaneously every 2 weeks or 420 mg monthly; or 300 mg subcutaneously at day 1, month 3, then every 6 months. These agents reduce LDL-C by approximately 50-60% on top of background therapy.
- •For patients with statin intolerance (confirmed myalgia or CK elevation not due to other causes), consider 180 mg daily. In CLEAR-Outcomes, it reduced LDL-C by 21% and hsCRP by 22% with no excess muscle symptoms, even in patients aged ≥75 years.
- •For severe hypertriglyceridemia (fasting triglycerides ≥500 mg/dL), start 160 mg daily to reduce pancreatitis risk. Add 2 g twice daily if triglycerides remain elevated or for residual cardiovascular risk. Do not use gemfibrozil with statins due to rhabdomyolysis risk; fenofibrate is the preferred fibrate for combination therapy.
- •Monitor hepatic transaminases and creatine kinase at baseline and 4-12 weeks after starting or dose-escalating any statin. Do not discontinue statins for mild, non-progressive myalgias without a dechallenge-rechallenge trial; the absolute excess risk of myalgia in double-blind trials is only 2.7 per 1000 patients.
- •Avoid ineffective or harmful therapies: policosanol, guggulipid, and red yeast rice have no proven LDL-C reduction beyond placebo. Niacin extended-release is no longer recommended due to lack of cardiovascular benefit and poor tolerability (25% discontinuation from flushing).
- •Refer to cardiology or a lipid specialist when FH is suspected (especially in young adults or children with LDL-C ≥190 mg/dL), triglycerides remain ≥1000 mg/dL despite fibrate therapy, or when statin intolerance requires advanced therapies like PCSK9 inhibitors or bempedoic acid.
- •For homozygous FH (HoFH) with LDL-C >100 mg/dL despite maximal pharmacotherapy, consider every 1-2 weeks; it acutely reduces LDL-C by 60-70% and, in registry data, reduces cardiovascular events by approximately 70%. Ensure cascade screening of all first-degree relatives of FH probands.
Board Review — High Yield
- •Tendon xanthomas, Pathognomonic for familial hypercholesterolemia (FH); palpate Achilles tendon with foot dorsiflexed; indicates need for genetic testing.
- •Dutch Lipid Clinic Network score, Definite FH: score >8 (uses LDL-C, family history, personal ASCVD, physical findings); >6 points suggests probable FH.
- •PCSK9 inhibitors, Evolocumab 140 mg SC q2w or 420 mg monthly; achieves ~60% LDL-C reduction; inclisiran 300 mg SC at day 1, month 3, then q6mo offers siRNA-based sustained reduction.
- •Bempedoic acid, Alternative for statin intolerance; reduces LDL-C by ~21% and hsCRP by ~22% without muscle toxicity (CLEAR-Outcomes).
- •Lp(a), Independent risk factor measured once in adults; ≥50 mg/dL (or ≥125 nmol/L) intensifies risk; no specific approved therapy yet, but it justifies more aggressive LDL-C lowering.
- •Severe hypertriglyceridemia, Triglycerides ≥500 mg/dL → risk of acute pancreatitis; first-line fibrate (fenofibrate 160 mg daily) plus lifestyle modification.
- •ASCVD risk scores, Pooled Cohort Equations for 10-year risk: high (≥20%), intermediate (7.5-20%), borderline (5-7.5%), low (<5%). Consider CAC scoring for intermediate risk.
- •Lipoprotein apheresis, For homozygous FH with LDL-C >100 mg/dL despite maximal drug therapy; reduces LDL-C by 60-70% per session every 1-2 weeks.
- •Statins in primary prevention, JUPITER: rosuvastatin 20 mg reduced major CV events by 44% (NNT ~95) in healthy individuals with hsCRP ≥2 and LDL-C <130 mg/dL.
- •Cascade screening, All first-degree relatives of FH probands should be screened with lipid panel and genetic testing if possible; identifies at least one affected relative in ~50% of families.
Deep Dive — Evidence Details
Definition, Classification and Nomenclature
- ▸The supplied evidence uses hyperlipidemia and dyslipidemia as related terms but does not provide a universal biochemical threshold. [220][236][243][248]
- ▸Primary or familial dyslipidemia is represented by the familial dyslipidemia category studied in children. [243]
- ▸Secondary hyperlipidemia is explicitly used as a distinct label in patients with depressive disorders. [236]
- ▸An LDL-C target of **<70 mg/dL** was used for vascular risk-factor control after stroke, but this target is not a definition of hyperlipidemia. [245]
- ▸The references support context-specific classification but do not establish formal numerical criteria for hypercholesterolemia, hypertriglyceridemia, or mixed dyslipidemia. [22][220][236][243][248]
Scope and terminology
Hyperlipidemia is used in the cited literature as a clinical diagnosis or phenotype indicating increased circulating lipid concentrations, but the supplied studies do not provide a universal biochemical threshold for the term. Accordingly, this section distinguishes the broad clinical term from the more specific term dyslipidemia, which may refer to an abnormal lipid pattern involving low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides, or combinations of these abnormalities. The references use “hyperlipidemia,” “hyperlipidaemia,” “dyslipidemia,” “familial dyslipidemia,” and “secondary hyperlipidemia” as related but not completely interchangeable labels. [220]C4[236][243][248]
The term should not be confused with an isolated cardiovascular risk measurement. LDL-C is one component of the lipid phenotype and is used as a treatment or risk-control target in some studies; for example, adults with prior stroke were assessed against an LDL-C target of <70 mg/dL, whereas a mobile screening program reported a median LDL-C of 103 mg/dL without defining that value as hyperlipidemia. [245][246] A lipid value should therefore be interpreted in clinical context rather than classified solely from the median values reported in observational cohorts. [245][246]
Practical classification
1. Primary or familial hyperlipidemia
Primary hyperlipidemia refers to lipid abnormalities attributable predominantly to inherited or intrinsic disorders rather than an identified acquired condition. The supplied evidence specifically describes children with “familial dyslipidemia,” indicating a familial category, and evaluated them against age-, sex-, and body-mass-index-matched controls. [243] The cited study does not establish diagnostic lipid cutoffs or a molecular subtype, so familial dyslipidemia should not be equated automatically with a particular genetic diagnosis on the basis of this reference alone. [243]
2. Secondary hyperlipidemia
Secondary hyperlipidemia denotes hyperlipidemia occurring in association with another condition, exposure, or clinical context. In the supplied literature, it is explicitly examined among patients with clinically diagnosed depressive disorders, and a prediction model was developed to identify patients at increased risk. [236] The study supports use of “secondary hyperlipidemia” as a distinct clinical label but does not, in the supplied abstract, enumerate a definitive causal checklist or establish that depression itself is a sufficient cause. [236]
Secondary hyperlipidemia should also be considered within broader metabolic assessment. Hyperlipidemia cohorts have been analyzed in relation to insulin resistance, estimated glucose disposal rate (eGDR), renal function, glycemic status, and mortality, but these associations do not by themselves define secondary causes. [220]C4[248] Similarly, a prospective study defined metabolically healthy non-obese participants partly by the absence of hyperlipidemia, diabetes, and concurrent hypertension, demonstrating that the term is used operationally in cohort eligibility criteria rather than as a standardized phenotype with one threshold. [22]B2b
3. Mixed or combined dyslipidemia
Mixed or combined dyslipidemia describes concurrent abnormalities in more than one lipid fraction, although the supplied references do not specify formal diagnostic criteria. This terminology is preferable when the abnormality cannot be accurately represented by LDL-C alone, particularly in populations characterized by obesity-related adiposity, insulin resistance, diabetes, or cardiometabolic disease. [22]B2b[244][248] HDL-C has been studied in relation to diabetic retinopathy and body roundness index, but the reported association does not establish that either HDL-C or body shape independently defines hyperlipidemia. [244]
4. Context-specific usage
The word “hyperlipidemia” may identify a study population without indicating severity, mechanism, or lipid fraction. A MIMIC-IV cohort consisted of critically ill patients diagnosed with hyperlipidemia and examined hemoglobin glycation index in relation to short-term mortality. [220]C4 Another NHANES analysis included 9,283 adults diagnosed with hyperlipidemia and evaluated eGDR, mortality, and mediation by estimated glomerular filtration rate. [248] These studies support the prognostic relevance of the diagnosis but do not establish a new nomenclature or severity classification. [220]C4[248]
Related terms and exclusions
“Dyslipidemia” is the broader and often preferred term when any lipid abnormality is present, including abnormalities not limited to elevated total cholesterol. “Hypercholesterolemia” should be reserved for cholesterol-predominant elevation, and “hypertriglyceridemia” for triglyceride-predominant elevation; however, the supplied references do not provide numerical thresholds for either term. The evidence also uses cardiometabolic risk terminology without redefining hyperlipidemia: adverse pregnancy outcomes, sleep apnea, fatty liver disease, hypertension, myocardial infarction, peripheral artery disease, and stroke are studied as associated conditions or outcomes rather than as nomenclatural subtypes. [234][235][237][238][239]C[242][245][247]
Several cited reports are unrelated to lipid classification, including studies of carotid web, coronary imaging, Alzheimer disease treatment, venous ulcers, and diabetic neuropathic pain; they provide no evidence for defining or classifying hyperlipidemia. [232][233][187]C4[240][241] Thus, the current evidence supports a mechanism- and context-based vocabulary—primary/familial, secondary, and mixed dyslipidemia—while leaving exact biochemical thresholds to externally established laboratory and guideline standards not included among the permitted references. [22]B2b[220]C4[236][243][245][248]
| Term | Use supported by the supplied references | Limitation |
|---|---|---|
| Hyperlipidemia/hyperlipidaemia | Broad clinical diagnosis or cohort phenotype involving abnormal lipid status [220]C4[245][248] | No universal threshold supplied [220]C4[248] |
| Dyslipidemia | General term used for lipid abnormalities, including familial disease [243][244] | Specific lipid-fraction criteria are not provided [243][244] |
| Familial dyslipidemia | Primary/inherited category described in children [243] | Molecular subtype and diagnostic cutoff are not established [243] |
| Secondary hyperlipidemia | Acquired or associated phenotype explicitly modeled in depressive disorders [236] | Causal criteria are not fully enumerated in the abstract [236] |
| LDL-C target | <70 mg/dL used for prior-stroke risk-factor control [245] | A management target, not a disease definition [245] |
Epidemiology and Risk Factors
- ▸The supplied evidence does not provide a general-population prevalence estimate for hyperlipidemia; most studies examine cardiometabolic comorbidity or use hyperlipidemia as a covariate. [22][58][250][257]
- ▸Older people living with HIV and adults with schizophrenia are specifically represented as populations in which hyperlipidemia is an important metabolic comorbidity requiring surveillance. [58][259]
- ▸Metabolically healthy non-obese status was defined as **BMI <30 kg/m²** with no diabetes, hypertension, or hyperlipidemia; visceral adiposity may identify risk not captured by BMI or waist circumference. [22]
- ▸One study defined metabolic syndrome as type 2 diabetes plus at least **two** of **BMI >30 kg/m²**, hypertension, or hyperlipidemia. [251]
- ▸Gestational diabetes, obesity-related disease, bariatric-surgery status, and selected medication exposures represent clinically relevant contexts for evaluating future or recurrent cardiometabolic disease, but the supplied abstracts do not provide hyperlipidemia-specific estimates. [252][254][261]
Scope of the available evidence
The supplied literature does not provide a population-wide estimate of hyperlipidemia prevalence or a contemporary global incidence trend. Instead, it describes hyperlipidemia as a component of broader cardiometabolic disease, a comorbidity in selected clinical populations, or a covariate in studies whose primary outcomes were unrelated to lipid disorders. [22]B2b[58]A1a[250][257] Accordingly, the evidence supports identification of high-risk groups but does not justify a single prevalence estimate applicable to the general population. [22]B2b[58]A1a[250]
Demographic and clinical epidemiology
Hyperlipidemia is specifically included among the cardiometabolic comorbidities studied in older people living with HIV, for whom a systematic review and meta-analysis synthesized worldwide evidence from studies published between 2013 and December 2023. [58]A1a The abstract supplied here does not report the pooled prevalence estimate, so no numerical prevalence should be assigned from this reference. [58]A1a
A Korean nationwide retrospective cohort followed 60,591 adults aged 20–65 years newly diagnosed with schizophrenia between 2012 and 2014 to quantify incident hyperlipidemia, hypertension, and type 2 diabetes after schizophrenia diagnosis. [259] The study therefore identifies schizophrenia as a population requiring longitudinal cardiometabolic surveillance, although the supplied abstract does not provide the incidence estimates or hazard ratios for hyperlipidemia. [259] Evidence from a Taiwanese nationwide cohort similarly examined physical illnesses during the 5 years after autism diagnosis in children diagnosed at ≤5 years, but the supplied abstract does not report hyperlipidemia-specific findings. [262]
The Guangdong Pharmaceutical University Occupational Health Cohort was established among Chinese coal-mining employees to characterize noncommunicable disease burden and identify occupationally vulnerable groups; its retrospective component covered 2009–2022, and its prospective component began in May 2023. [250] Of 36,577 workers with routine examinations in 2023, 25,597 were eligible employees, but the supplied abstract does not state the cohort’s hyperlipidemia prevalence. [250]
Obesity, adiposity, and metabolic syndrome
Hyperlipidemia commonly appears as part of a clustered cardiometabolic phenotype rather than as an isolated exposure in the supplied studies. [22]B2b[251][258] In a prospective UK Biobank study of 22,040 metabolically healthy non-obese participants, metabolically healthy non-obese status was defined using BMI <30 kg/m², absence of diabetes, and absence of concurrent hypertension or hyperlipidemia. [22]B2b The study assessed visceral and subcutaneous adipose-tissue volumes by whole-body MRI and specifically investigated whether unfavorable visceral adiposity could identify risk not captured by BMI or waist circumference. [22]B2b Thus, apparently normal anthropometric status does not necessarily exclude adverse adipose distribution as a cardiometabolic risk marker, although the supplied abstract does not provide hyperlipidemia-specific effect estimates. [22]B2b
In a claims-based arthroplasty study, metabolic syndrome was operationalized as type 2 diabetes plus at least two of the following: BMI >30 kg/m², hypertension, or hyperlipidemia. [251] A separate real-world cohort evaluated cardiometabolic disease as a modifier of outcomes among patients with knee osteoarthritis receiving intra-articular hyaluronic acid, but the supplied abstract does not provide lipid-specific risk estimates. [258] After metabolic and bariatric surgery, hyperlipidemia was one of the obesity-related medical conditions assessed for initial remission and subsequent recurrence; the study included patients with at least 36 months of follow-up and at least 20% total weight loss, but the supplied abstract does not report recurrence estimates specific to hyperlipidemia. [261]
Disease-associated and treatment-associated risk contexts
Pregnancy-related metabolic disease may identify later cardiometabolic vulnerability. [252] A retrospective MarketScan cohort examined incident postpartum cardiovascular, kidney, and metabolic disorders after gestational diabetes among commercially insured females aged 12–55 years with no preexisting cardiovascular-kidney-metabolic disorder before delivery; the supplied abstract does not specify the incidence of postpartum hyperlipidemia. [252] Adverse pregnancy outcomes were also studied in relation to long-term peripheral artery disease in 2,201,446 women delivering singleton infants in Sweden from 1973–2015, but that study addresses vascular disease rather than hyperlipidemia directly. [235]
Medication and disease-specific contexts may alter lipid-related risk. [254] Bexarotene is described as having predictable but substantial metabolic toxicity in patients with mycosis fungoides; in a propensity-matched real-world cohort of 2,242 patients per group, exposure was not associated with a significant increase in the composite adapted major adverse cardiovascular event endpoint over a median 4.0-year follow-up, although this does not establish absence of dyslipidemia. [254] Hyperlipidemia was also included among candidate predictors of second cancer in a cohort of 1,968 patients with polycythemia vera or essential thrombocythemia followed for a median 11.2 years, but the supplied abstract does not report its adjusted effect estimate. [260]
Cardiovascular and comorbidity relevance
Several studies reinforce that hyperlipidemia is clinically relevant because it is embedded within cardiovascular-risk assessment. [233][256]C[257] A Jordanian electronic-health-record study used approximately 600,000 individuals to develop pharmacotherapy-informed cardiovascular-risk prediction models incorporating demographics, blood pressure, laboratory data, and medications; the supplied abstract does not provide hyperlipidemia-specific model performance. [257] Studies of emergency-department chest-pain imaging, complex aortoiliac occlusive disease, and cardiometabolic disease in osteoarthritis address cardiovascular or vascular outcomes but do not provide hyperlipidemia prevalence estimates. [233][256]C[258]
The remaining supplied studies concern systemic-lupus-associated osteonecrosis, pregnancy-associated acute kidney injury, occupational stress after the Deepwater Horizon spill, cataract-surgery complications, adverse pregnancy outcomes, and physical illness after autism diagnosis; their abstracts do not provide direct epidemiologic estimates or validated risk-factor effect sizes for hyperlipidemia. [249][253][255][158]B2b[235][262] These evidence gaps should be made explicit when applying the available literature to routine hyperlipidemia risk assessment.
| Risk context or population | Evidence relevant to hyperlipidemia | Limitation |
|---|---|---|
| Older people living with HIV | Systematic review and meta-analysis assessed worldwide prevalence of high cholesterol among older people living with HIV. [58]A1a | Pooled estimate not provided in the supplied abstract. [58]A1a |
| Schizophrenia | Nationwide Korean cohort quantified incident cardiometabolic comorbidities, including hyperlipidemia, after diagnosis. [259] | Incidence estimates not provided in the supplied abstract. [259] |
| Visceral adiposity | UK Biobank study assessed MRI-derived visceral and subcutaneous fat among 22,040 metabolically healthy non-obese adults. [22]B2b | No hyperlipidemia-specific effect estimate supplied. [22]B2b |
| Metabolic syndrome | Defined as type 2 diabetes plus at least two of BMI >30 kg/m², hypertension, or hyperlipidemia. [251] | Definition was used for an arthroplasty cohort, not population surveillance. [251] |
| Bexarotene exposure | Described as having predictable metabolic toxicity in mycosis fungoides. [254] | Cardiovascular safety outcome did not establish dyslipidemia risk. [254] |
| Bariatric surgery | Hyperlipidemia was assessed for remission and recurrence after substantial weight loss. [261] | Hyperlipidemia-specific recurrence results not supplied. [261] |
Pathophysiology and Mechanism
- ▸Visceral adiposity can confer cardiometabolic risk despite normal BMI and waist circumference. [22]
- ▸Insulin resistance and kidney dysfunction may interact with hyperlipidemia in determining mortality risk, but observational mediation does not prove causality. [248]
- ▸Atherogenic lipid exposure contributes to vascular remodeling and plaque-related disease within a broader network of vascular risk factors. [245][247][269][270]
- ▸Experimental and clinical evidence links hyperlipidemia with cardiac remodeling, epicardial adiposity, myocardial stress, and profibrotic signaling. [243][263][265]
- ▸Saturated fatty-acid lipotoxicity can promote mesangial-cell apoptosis and endoplasmic-reticulum stress, with FGF21-SIRT1 investigated as a protective pathway. [267]
- ▸QDPR variation may modify diabetes and diabetic kidney disease accompanied by hyperlipidemia through tetrahydrobiopterin-related biology. [266]
- ▸Evidence concerning cataract, epiretinal membrane, limb ischemia, vasculitis, and cardiomyopathy is mainly associative or disease-specific and should not be interpreted as proof of a direct hyperlipidemia mechanism. [92][121][239][264][271][272][273]
Overview
Hyperlipidemia is a heterogeneous metabolic state characterized by increased circulating atherogenic lipoproteins, triglyceride-rich particles, or both. Its clinical consequences arise from the interaction of lipid accumulation, endothelial dysfunction, vascular inflammation, insulin resistance, oxidative stress, and tissue-specific lipotoxicity rather than from serum lipid elevation alone. The supplied evidence includes animal experiments, human cohort and cross-sectional studies, genetic analyses, and disease-specific observational studies; therefore, mechanistic inferences should be interpreted according to study design and should not be assumed to establish causality in humans. [22]B2b[243][248]
Lipid accumulation, visceral adiposity, and metabolic dysfunction
Visceral adipose tissue (VAT) is metabolically active and can promote cardiometabolic disease through free-fatty-acid release, inflammatory signaling, and adipokine dysregulation. In a prospective cohort of 22,040 metabolically healthy non-obese UK Biobank participants, whole-body MRI was used to quantify VAT and subcutaneous adipose tissue, with sex-specific VAT-to-SAT ratio thresholds derived from the German National Cohort; the study specifically addressed occult visceral adiposity not captured by BMI or waist circumference. [22]B2b These findings support the concept that apparently normal anthropometric measurements do not exclude a biologically adverse adipose-tissue distribution, although the supplied abstract does not provide the outcome estimates. [22]B2b
Insulin resistance provides an important mechanistic link between dyslipidemia and adverse outcomes. In 9,283 adults with hyperlipidemia from NHANES 2005–2018, estimated glucose disposal rate (eGDR), a non-invasive marker of insulin resistance, was evaluated in relation to all-cause and cardiovascular mortality, with estimated glomerular filtration rate examined as a potential mediator. [248] This framework is consistent with an interconnected pathway in which insulin resistance, dyslipidemia, and kidney dysfunction amplify one another; however, the observational design cannot prove that insulin resistance or reduced eGFR directly mediates lipid-related mortality. [248]
Atherosclerosis and vascular injury
Atherogenic lipoproteins can enter the arterial intima, undergo modification, and promote monocyte recruitment, foam-cell formation, plaque growth, and vascular remodeling. The supplied clinical studies support the vascular relevance of lipid-related risk but do not directly measure each molecular step. Among adults with prior stroke surveyed from 1999–2023, guideline-based secondary-prevention control included LDL cholesterol <70 mg/dL, alongside blood pressure, glycemic, and smoking targets; the study assessed temporal control of these risk factors rather than testing a molecular mechanism. [245] A mobile-health screening program in socially disadvantaged urban communities likewise identified incompletely controlled cardiometabolic risk, including a median LDL cholesterol of 103 mg/dL, illustrating the population-level persistence of modifiable lipid exposure. [246]
Cerebral and retinal microvascular findings provide additional evidence of vascular remodeling associated with systemic cardiometabolic disease. Four-dimensional-flow MRI was used to examine the relationship between brain-artery remodeling, hemodynamics, and cerebral small-vessel disease, while fundus fluorescein angiography studies evaluated retinal circulation and caliber biomarkers in relation to cerebral small-vessel-disease burden. [247][269] In a separate study, carotid plaque burden was related to retinal vascular parameters, and diabetes modified this association. [270] These studies support shared macrovascular and microvascular vascular pathology, but they do not establish hyperlipidemia as the sole cause because the populations also included other vascular risk factors. [247][269][270]
Cardiac remodeling and lipotoxicity
Hyperlipidemic stress may contribute to myocardial injury and remodeling through lipid deposition, inflammatory activation, oxidative stress, and profibrotic signaling. In female Yucatan miniswine exposed for 8 weeks to a high-cholesterol diet, hyperlipidemia induced cardiac remodeling-associated changes assessed by histology, gene expression, protein analysis, and immunohistochemistry; the investigation focused on galectin-3, transforming growth factor-β1, and brain natriuretic peptide. [265]C These mediators link myocardial stress with extracellular-matrix remodeling and fibrosis, although the abstract describes an experimental model and does not establish the relative contribution of each pathway in human hyperlipidemia. [265]C
Epicardial adipose tissue may provide a local cardiac mechanism because it is a visceral-fat depot capable of releasing bioactive molecules that influence myocardial function and atherosclerosis. In a prospective case-control study of 21 children with familial dyslipidemia and 21 age-, sex-, and BMI-matched controls, epicardial fat thickness and left-ventricular systolic and diastolic function were assessed by echocardiography. [243] The study supports an association between familial dyslipidemia, epicardial adiposity, and cardiac functional abnormalities, but matching and cross-sectional design limit causal interpretation. [243]
Chronic pain may intensify lipid-related cardiac injury. In 32 male apolipoprotein E-deficient mice receiving a high-fat diet, spared-nerve-injury chronic pain was initiated at different time points and cardiac function, mechanical allodynia, and anxiety-like behavior were assessed. [263] The reported mechanism involved the c-Jun N-terminal kinase 1/silent information regulator 1 (JNK1/SIRT1) signaling axis, supporting a model in which chronic nociceptive stress synergizes with atherogenic dietary exposure to worsen myocardial injury. [263] Because this was a small, male, genetically modified mouse study, translation to human hyperlipidemia remains uncertain. [263]
Organ-specific lipotoxicity and genetic modifiers
In diabetic nephropathy, palmitic-acid exposure injured human mesangial cells through apoptosis and endoplasmic-reticulum stress, while FGF21 and SIRT1 were investigated as protective components of a signaling axis. [267] This provides cellular evidence that saturated free fatty acids can cause renal lipotoxicity and that metabolic stress-response pathways may counteract it. [267] A Chinese Han genetic study further examined QDPR rs3733570 in type 2 diabetes and diabetic kidney disease accompanied by hyperlipidemia, implicating tetrahydrobiopterin homeostasis as a possible genetic modifier of metabolic and renal vascular injury. [266]
Hyperlipidemia may also affect nonvascular tissues, although the supplied evidence is primarily associative. A clinic-based study of 384 age-related cataract subjects examined lipid indices by cataract subtype, including cortical, nuclear, and posterior subcapsular cataract, because metabolic imbalance may impair lens epithelial-cell function. [121]C4 Machine-learning analysis of 2,015 idiopathic epiretinal membrane cases with matched controls and 3,175 secondary epiretinal membrane cases with matched controls identified systemic associations, but the supplied abstract does not establish a lipid-specific causal pathway. [264] JAK-STAT signaling has been implicated in generalized granuloma annulare, but the systematic review concerns inflammatory skin disease and JAK-inhibitor treatment rather than hyperlipidemia pathogenesis. [92]B2a
Clinical modifiers and limits of inference
Peripheral arterial disease, wound healing, and cardiovascular outcomes are influenced by perfusion, infection, inflammation, diabetes, and treatment in addition to lipid exposure. A retrospective study of WIfI stage 3–4 chronic limb-threatening ischemia evaluated wound-healing time, wound-free period, and amputation-free survival across revascularization and wound-care strategies, but the supplied evidence does not isolate hyperlipidemia as a mechanism. [239]C Similarly, studies of ANCA-associated vasculitis, atrial fibrillation with acute myocardial infarction, and non-dilated cardiomyopathy evaluated echocardiographic or strain predictors of cardiovascular events rather than lipid biology directly. [271][272][273] Overall, hyperlipidemia should be understood as one component of a multisystem network in which lipid burden interacts with adipose distribution, insulin resistance, inflammation, genetic susceptibility, kidney dysfunction, and established vascular disease. [22]B2b[243][248][263][265]C[266][267][270]
| Domain | Evidence and interpretation |
|---|---|
| Adipose tissue | MRI-defined VAT/SAT distribution may identify hidden cardiometabolic risk in non-obese individuals. [22]B2b |
| Insulin resistance and kidney disease | eGDR and eGFR were evaluated as linked determinants of mortality in hyperlipidemic adults. [248] |
| Cardiac remodeling | Galectin-3, TGF-β1, BNP, epicardial fat, and JNK1/SIRT1 were investigated in experimental or clinical cardiac injury. [243][263][265]C |
| Renal lipotoxicity | Palmitic acid induced mesangial-cell apoptosis and endoplasmic-reticulum stress; FGF21-SIRT1 was examined as protective. [267] |
| Vascular disease | Plaque burden, brain-artery remodeling, retinal hemodynamics, and secondary-stroke risk-factor control were evaluated. [245][247][269][270] |
| Genetic susceptibility | QDPR rs3733570 was studied in diabetes and diabetic kidney disease accompanied by hyperlipidemia. [266] |
Clinical Presentation
- ▸Hyperlipidemia is often asymptomatic and detected during cardiometabolic screening or evaluation of comorbid disease [22, 246].
- ▸A **BMI <30 kg/m²** does not exclude unfavorable visceral adiposity or cardiometabolic risk [22].
- ▸Secondary hyperlipidemia may occur with depression, obesity-related disease, sleep apnea, fatty liver disease, diabetes, kidney transplantation, and severe systemic illness [220, 236, 237, 274, 275].
- ▸Children with familial dyslipidemia may have subclinical epicardial adiposity or cardiac functional abnormalities despite limited symptoms [243].
- ▸In established vascular disease, an **LDL cholesterol target <70 mg/dL** is used for secondary stroke prevention [245].
- ▸Focal neurologic events in a patient with hyperlipidemia require evaluation for alternative vascular causes, including carotid web [232].
Overview
Hyperlipidemia is frequently clinically silent and may be detected incidentally through lipid testing or opportunistic cardiometabolic screening rather than by lipid-specific symptoms. In a prospective UK Biobank cohort, metabolically healthy non-obese adults were defined by BMI <30 kg/m², absence of diabetes and hypertension, and absence of hyperlipidemia, illustrating that dyslipidemia is commonly incorporated into cardiometabolic risk classification even when individuals have no overt disease manifestations [22]B2b. Community-based mobile health-unit screening identified uncontrolled cardiometabolic risk factors, including modestly elevated low-density lipoprotein cholesterol, among adults who presented for screening rather than for lipid-related complaints [246].
Common associated phenotype
Clinical presentation commonly reflects the metabolic conditions that accompany or cause dyslipidemia rather than elevated cholesterol itself. Unfavorable visceral adiposity may occur despite a normal or non-obese phenotype and may not be fully captured by BMI or waist circumference; MRI-based assessment of visceral and subcutaneous adipose tissue was used to identify this hidden risk in metabolically healthy non-obese individuals [22]B2b. Secondary hyperlipidemia has also been specifically investigated in patients with depression, with a predictive model incorporating body composition, metabolic variables, and clinical characteristics, indicating that lipid abnormalities may emerge in the context of broader psychiatric and metabolic disease [236]. Sleep apnea is similarly associated with increased risk of non-alcoholic fatty liver disease, and studies in this population integrate anthropometric, biochemical, and comorbidity data when evaluating metabolic presentation [237].
Hepatic steatosis may accompany dyslipidemia and other components of cardiometabolic-renal disease. Among kidney-transplant recipients without steatosis before transplantation, 30.1% developed de novo hepatic steatosis during follow-up, supporting the importance of assessing liver and metabolic abnormalities in patients with complex cardiovascular risk [275]. In adults with type 2 diabetes, higher triglyceride–HDL cholesterol–glucose body index values were positively and linearly associated with hyperuricemia and gout, suggesting that dyslipidemia may present alongside disordered glucose metabolism and urate-related disease [274].
Pediatric and familial dyslipidemia
Children with familial dyslipidemia may remain clinically well but can demonstrate early subclinical cardiovascular involvement. In a prospective case-control study, children with familial dyslipidemia underwent lipid profiling and echocardiography because of concern for epicardial adiposity and cardiac effects; the investigation evaluated epicardial fat thickness and left-ventricular systolic and diastolic function against age-, sex-, and BMI-matched controls [243]. Thus, the absence of symptoms does not exclude early cardiac structural or functional abnormalities in pediatric dyslipidemia [243].
Vascular and end-organ manifestations
When dyslipidemia contributes to atherosclerotic disease, presentation may occur through vascular events rather than lipid-related symptoms. In adults with a prior stroke, guideline-based secondary-prevention assessment included an LDL cholesterol target <70 mg/dL, together with blood-pressure, glycemic, and smoking targets, underscoring the clinical importance of recognizing hyperlipidemia in patients presenting after cerebrovascular disease [245]. Coronary artery calcium measured on non-gated, non-contrast chest CT was evaluated as a marker associated with cardiovascular and transplant-related outcomes in lung-transplant recipients, supporting the use of subclinical coronary atherosclerosis markers when symptoms are absent [276].
Ischemic neurologic symptoms should not automatically be attributed to dyslipidemia. A carotid web is a distinct vascular lesion diagnosed by digital-subtraction angiography and is investigated in relation to ischemic stroke, transient ischemic attack, and recurrent ipsilateral ischemic events [232]. This represents an important alternative or coexisting explanation for focal neurologic presentation in a patient who also has hyperlipidemia [232].
Special clinical contexts
In pregnancy, hyperglycemia identified by oral glucose-tolerance testing and gestational weight gain were evaluated as determinants of adverse fetomaternal outcomes in women with gestational diabetes, emphasizing that dyslipidemia-related assessment may occur within a broader metabolic-risk presentation rather than as an isolated disorder [234]. Adverse pregnancy outcomes have also been associated with increased long-term risk of peripheral artery disease, making prior obstetric history relevant when assessing later vascular risk in women with dyslipidemia [235].
Severe illness may alter the apparent presentation and prognosis of hyperlipidemia. In a retrospective MIMIC-IV cohort of 3,229 critically ill patients with hyperlipidemia, hemoglobin glycation index was examined in relation to in-hospital and 28-day mortality, indicating that critically ill patients may present with dyslipidemia alongside substantial glycemic dysregulation and systemic disease [220]C4. Bariatric and metabolic surgery cohorts further demonstrate that severe obesity may present with multiple associated medical problems and require longitudinal assessment of weight, nutrition, complications, and quality of life after treatment [108]B2b.
Clinical interpretation
Hyperlipidemia should therefore be suspected or assessed in asymptomatic individuals with obesity or visceral adiposity, diabetes, hypertension, sleep apnea, fatty liver disease, depression, chronic kidney or transplant-related disease, familial lipid disorders, or established vascular disease [22]B2b[108]B2b[220]C4[236][237][243][245][275]. Evidence supplied here does not establish that sudden deafness, retinal microvascular abnormalities, lower-gastrointestinal rebleeding, autism-associated physical illness, or pharmacogenomic myocardial-infarction prediction is a characteristic presentation of hyperlipidemia; these studies address separate clinical questions and should not be used to define lipid-specific symptoms [109]A1a[238][262][269][277].
| Clinical context | Relevant presentation or assessment | Reference |
|---|---|---|
| Metabolically healthy or non-obese individuals | Visceral adiposity may be present despite BMI <30 kg/m² and apparently low conventional risk | [22]B2b |
| Community screening | Elevated LDL cholesterol may be detected without lipid-specific symptoms | [246] |
| Familial dyslipidemia in children | Possible epicardial adiposity and subclinical left-ventricular abnormalities | [243] |
| Diabetes or metabolic syndrome | Dyslipidemia may coexist with hyperuricemia, gout, or retinopathy-related risk assessment | [244][274] |
| Sleep apnea, depression, or transplant status | Consider secondary hyperlipidemia and associated fatty liver or metabolic disease | [236][237][275] |
| Established vascular disease | May present through stroke or coronary atherosclerosis rather than lipid symptoms | [245][276] |
Diagnosis and Workup
- ▸Confirm suspected hyperlipidemia with a lipid profile; the supplied evidence does not provide universal diagnostic cutoffs for LDL-cholesterol, triglycerides, HDL-cholesterol, or total cholesterol. [22] [220] [243]
- ▸Document secondary causes and associated disease, including diabetes, hypertension, obesity or visceral adiposity, depression-related risk, MASLD/NAFLD, sleep apnea, pregnancy-related risk, kidney disease, liver disease, thyroid disease, and medication exposure. [22] [125] [223] [234] [235] [236] [237]
- ▸For adults with prior stroke, the cited risk-control definition uses LDL-cholesterol **<70 mg/dL**. [245]
- ▸Coronary calcium scoring, angiography, carotid imaging, echocardiography, retinal imaging, and neurologic testing are adjunctive, risk-directed evaluations rather than diagnostic replacements for lipid testing. [232] [243] [269] [270] [276] [278]
- ▸Animal, cross-sectional, retrospective, and machine-learning studies should not be interpreted as validating new diagnostic criteria. [22] [121] [125] [220] [236] [237] [263] [269]
Diagnostic scope and confirmation
Hyperlipidemia should be confirmed with laboratory lipid assessment and interpreted in clinical context rather than inferred from a single cardiovascular or metabolic finding. In the available studies, lipid status was assessed using serum lipid profiles or LDL-cholesterol measurements, while some cohorts defined hyperlipidemia as an existing comorbidity or diagnosis. [220]C4 [22]B2b [236] [243] The supplied evidence does not establish a universal diagnostic cutoff for total cholesterol, LDL-cholesterol, triglycerides, or HDL-cholesterol; therefore, local laboratory reference ranges and the applicable professional guideline should be used when classifying an individual result. [22]B2b [220]C4 [243]
Obtain a complete fasting or nonfasting lipid profile according to local practice, including total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglycerides. The evidence set specifically demonstrates clinical use of LDL-cholesterol for risk-control assessment, including a target of <70 mg/dL in adults with prior stroke. [245] HDL-cholesterol was examined as a vascular-metabolic exposure in adults with diabetes, and body roundness index was evaluated as a potential mediator of its association with diabetic retinopathy. [244] In children with familial dyslipidemia, lipid-profile assessment was paired with clinical examination and echocardiography. [243]
History and examination
The initial assessment should document age, sex, family history of premature atherosclerotic disease or markedly abnormal lipids, diet, alcohol exposure, weight trajectory, medications, pregnancy history, diabetes, hypertension, kidney disease, liver disease, thyroid disease, inflammatory disease, and other potential secondary causes. This broad clinical context is supported by studies examining secondary hyperlipidemia in depression, cardiometabolic disease in apparently healthy adults, metabolic liver disease, pregnancy-related risk, and chronic systemic disease. [236] [22]B2b [125]C4 [234] [235]
Record body-mass index, waist circumference, blood pressure, glycemic status, and relevant comorbidities. The UK Biobank study defined metabolically healthy non-obese individuals as having BMI <30 kg/m² and no diabetes, concurrent hypertension, or hyperlipidemia, illustrating that absence of obesity or a conventional diagnosis does not exclude unfavorable visceral adiposity. [22]B2b Whole-body MRI-derived visceral-to-subcutaneous adipose-tissue ratios identified additional cardiometabolic risk in this apparently low-risk group. [22]B2b In patients with sleep-apnea syndrome, anthropometric, biochemical, and comorbidity data were integrated into models for non-alcoholic fatty liver disease, supporting assessment for obesity-related hepatic disease when dyslipidemia coexists with sleep-disordered breathing. [237]
Evaluation for secondary causes and associated metabolic disease
Assess glycemia with appropriate glucose testing and HbA1c when clinically indicated. Hyperglycemia phenotypes defined by 75-g oral glucose-tolerance testing were associated with pregnancy outcomes in women with gestational diabetes, while hemoglobin glycation index was studied as a prognostic marker among critically ill patients diagnosed with hyperlipidemia. [234] [220]C4 These studies support documenting glycemic status, but they do not validate hemoglobin glycation index as a diagnostic test for hyperlipidemia. [220]C4
Review medications and psychiatric history in patients with depression, because a two-cohort machine-learning study specifically evaluated predictors of secondary hyperlipidemia in this population. [236] Evaluate hepatic steatosis and fibrosis risk when clinically appropriate. MASLD was investigated using fatty liver index criteria and serum Mac-2 binding protein glycan isomer in relation to cerebral small-vessel disease, and a separate multicenter model examined NAFLD risk in sleep-apnea syndrome. [125]C4 [237] These data support assessment of metabolic liver disease as a possible associated condition, not use of these biomarkers as lipid diagnostic substitutes. [125]C4 [237]
Pregnancy and reproductive history should be documented. Gestational weight gain and oral-glucose-tolerance-test hyperglycemia were independently and synergistically associated with adverse feto-maternal outcomes in women with gestational diabetes, and adverse pregnancy outcomes were associated with later peripheral artery disease in a nationwide Swedish cohort. [234] [235] These findings justify incorporating pregnancy history into long-term vascular-risk assessment, although they do not define hyperlipidemia.
Cardiovascular and end-organ assessment
Determine whether the patient has established atherosclerotic disease, including prior stroke, peripheral artery disease, coronary disease, or carotid disease, because treatment targets and urgency of evaluation may differ. In US adults with prior stroke, guideline-recommended LDL-cholesterol control was defined as <70 mg/dL; the study also assessed blood pressure, HbA1c, and smoking control. [245] Mobile health-unit screening identified uncontrolled cardiometabolic risk factors in socially disadvantaged urban communities and included medical history, blood pressure, LDL-cholesterol, and HbA1c testing. [246]
Additional testing should be symptom- and risk-directed rather than routine. Coronary artery calcium obtained from non-gated, noncontrast chest CT was evaluated for prediction of cardiovascular and transplant-related outcomes in lung-transplant recipients, and invasive coronary angiography was used to assess obstructive coronary disease. [276] Digital-subtraction angiography characterized carotid webs in patients with ischemic cerebrovascular events; a carotid web is an anatomic vascular lesion and should not be conflated with lipid-mediated atherosclerosis. [232] Carotid plaque burden assessed by head-and-neck CT angiography was associated with retinal vascular parameters, with diabetes modifying these relationships. [270]
Echocardiography is not a diagnostic test for hyperlipidemia but may evaluate suspected cardiac consequences or comorbidity. It was used to assess left-ventricular function and epicardial fat in children with familial dyslipidemia. [243] Experimental evidence in apolipoprotein-E-deficient mice indicates that high-fat diet and chronic pain can synergize through the JNK1/SIRT1 axis to promote cardiac injury, but this animal evidence cannot be used to diagnose human hyperlipidemia or determine clinical cardiac workup. [263]
Ocular and neurologic tests are likewise adjunctive. Serum and ocular studies investigated associations between lipid-related or metabolic measures and cataract, diabetic retinopathy, retinal microvasculopathy, and cerebral small-vessel disease. [121]C4 [244] [269] [278] These findings may inform evaluation of end-organ disease in selected patients but do not replace lipid measurement. [121]C4 [244] [269] [278]
Interpretation and limitations
Machine-learning models, imaging biomarkers, and observational associations in the cited studies may assist risk stratification, but they are not established stand-alone diagnostic criteria for hyperlipidemia. [22]B2b [236] [237] [269] The workup should therefore prioritize confirmed lipid measurements, identification of secondary causes, characterization of global cardiovascular risk, and targeted evaluation for established or suspected end-organ disease. [220]C4 [245] [246]
| Workup component | Evidence-based purpose |
|---|---|
| Lipid profile | Confirm and characterize the lipid abnormality; studies used serum lipid measures or LDL-cholesterol. [220]C4 [236] [243] |
| Glycemic assessment | Identify diabetes or hyperglycemia; OGTT and HbA1c-related measures were used in metabolic and pregnancy cohorts. [220]C4 [234] |
| Anthropometry and blood pressure | Detect cardiometabolic risk not captured by lipid values alone; visceral adiposity may be present despite BMI <30 kg/m². [22]B2b [246] |
| Liver assessment | Evaluate associated MASLD/NAFLD and fibrosis risk, particularly with metabolic disease or sleep apnea. [125]C4 [237] |
| Atherosclerotic disease assessment | Establish prior stroke, PAD, coronary disease, carotid plaque, or other disease that changes risk interpretation. [232] [245] [270] [276] |
| Targeted end-organ testing | Use echocardiography, retinal imaging, or neurologic evaluation when cardiac, ocular, or cerebrovascular disease is suspected. [243] [269] [278] |
Severity Staging and Risk Stratification
- ▸No LDL-C, non-HDL-C, triglyceride, or total-cholesterol severity thresholds are established by the supplied evidence; biochemical staging should not be inferred from these studies. [132][279][257]
- ▸Established ASCVD, particularly prior MI or PAD, places a patient in a high clinical-risk context independent of the isolated lipid value. [279][289]
- ▸Metabolic risk may remain substantial despite BMI <30 kg/m² or absence of conventional diagnoses when visceral adiposity is unfavorable. [22]
- ▸Hyperlipidemia is a recognized etiologic context for acute pancreatitis, but the supplied evidence does not provide a lipid-specific pancreatitis threshold. [280]
- ▸Perioperative assessment should document lipid-lowering therapy received within 90 days before surgery and consider 30-day postoperative cardiovascular outcomes. [132]
Scope and interpretation
Hyperlipidemia should be staged according to both the lipid phenotype and the patient’s underlying atherosclerotic cardiovascular disease (ASCVD), metabolic, pancreatic, and treatment-related risk. The supplied contemporary evidence does not provide a validated LDL-C, non-HDL-C, triglyceride, or total-cholesterol threshold for assigning biochemical severity; therefore, numerical lipid cutoffs should not be inferred from these studies. Instead, risk stratification should combine lipid measurements with established disease status, comorbidities, treatment intensity, and the clinical context. [132]B2b[279][257]
Clinical severity domains
Established or very-high-risk ASCVD. Patients with prior myocardial infarction (MI), coronary disease, peripheral arterial disease, or other documented ASCVD should be considered clinically high risk regardless of the isolated lipid value. In a prospective cohort of 1,283 patients after MI treated with percutaneous coronary intervention, circulating metals were evaluated for incremental mortality prediction beyond the GRACE score; the multivariable models included hyperlipidemia together with age, sex, body mass index, smoking, diabetes, hypertension, and renal function. This supports interpreting hyperlipidemia as one component of a broader post-MI risk profile rather than as a standalone prognostic classifier. [279] Patients with MI may also have more extensive coronary disease according to their clinical characteristics and habitual activity, although the cited study did not establish a lipid-specific staging system. [284]
Metabolic and adiposity-associated risk. Absence of obesity, diabetes, hypertension, and hyperlipidemia was required to classify participants as metabolically healthy non-obese in a prospective UK Biobank cohort of 22,040 individuals. The study assessed visceral and subcutaneous adipose tissue using whole-body MRI and derived sex-specific visceral-to-subcutaneous adipose tissue ratio cutoffs from an external cohort. Accordingly, a normal BMI or the absence of conventional metabolic diagnoses should not be treated as proof of low cardiometabolic risk when unfavorable visceral adiposity is present. [22]B2b In patients with sepsis, metabolic syndrome was present in 44.0% of 2,973 adults in a multicenter Chinese cohort, and the association between metabolic syndrome and in-hospital mortality varied with illness severity; the study specifically examined individual components, including hyperlipidemia. These findings support documenting hyperlipidemia within the metabolic-syndrome context while avoiding direct extrapolation of sepsis outcomes to chronic lipid management. [282]
Pancreatitis risk. Hyperlipidemia was identified as one of the principal etiologic categories considered in a retrospective cohort study of acute pancreatitis that compared single-etiology and mixed-etiology disease and developed an early severity-prediction model. Because the supplied abstract does not report a triglyceride threshold or a lipid-specific effect estimate, it supports recognizing hyperlipidemia as a potentially important pancreatitis context but does not justify a numerical pancreatitis severity stage. [280]
Treatment- and perioperative risk. In a nationwide, propensity-score-matched active-comparator cohort, adults with hyperlipidemia who underwent surgery at U.S. institutions received either a PCSK9 inhibitor or a statin within 90 days before surgery. The primary endpoint was 30-day postoperative major adverse cardiovascular events. This study is relevant to risk assessment because treatment class and perioperative exposure may modify management considerations in patients with substantial lipid-related cardiovascular risk; however, the supplied abstract does not provide the comparative event estimates or establish that PCSK9 therapy defines a separate hyperlipidemia severity category. [132]B2b Perioperative risk should also account for non-lipid factors, including malignancy and procedure-specific thromboembolic risk; a systematic review and meta-analysis addressed postoperative venous thromboembolism after lung-cancer surgery, but its supplied abstract does not identify hyperlipidemia as a validated staging variable. [131]B2a
Practical risk-stratification framework
- Confirm the lipid phenotype and persistence: record serial lipid results, treatment status, and suspected secondary contributors; the cited evidence supports dynamic lipid monitoring in selected oncology settings but does not validate a universal trajectory-based staging system. [118]B2b
- Assign clinical risk first: document prior MI, coronary disease, PAD, diabetes, hypertension, chronic kidney disease, and other major comorbidities because these variables are incorporated into contemporary cardiovascular prediction approaches. [279][257]
- Identify metabolic amplification: assess obesity, visceral adiposity, metabolic syndrome, and cardiometabolic clustering even when BMI is below 30 kg/m². [22]B2b[282]
- Screen for complication-specific contexts: consider pancreatitis when hyperlipidemia accompanies acute abdominal illness and evaluate perioperative cardiovascular risk when lipid-lowering therapy was used before surgery. [280][132]B2b
- Use validated risk models cautiously: real-world machine-learning models using electronic health-record and pharmacotherapy data may improve individualized prediction in some populations, but external calibration and generalizability remain essential. [257] Ten-year ASCVD/Framingham risk assessment has been examined in older adults with stage I–II non-small-cell lung cancer receiving stereotactic body radiation therapy, illustrating the value of formal risk estimation in cancer populations, although it is not a hyperlipidemia-specific staging tool. [287]
Evidence limitations
The cited literature primarily evaluates outcomes, comorbidity associations, or treatment comparisons rather than defining biochemical hyperlipidemia stages. Several studies are retrospective or population-specific, and findings from sepsis, cancer, post-MI, pancreatitis, or perioperative cohorts should not be directly generalized to routine lipid classification. [118]B2b[131]B2a[132]B2b[257][280][282][287] Other cited studies address cardiovascular or metabolic outcomes in specialized conditions, including discoid lupus erythematosus, immune-checkpoint inhibitor exposure, and aortic stenosis; they may inform comorbidity review but do not establish lipid thresholds or severity categories. [286][289][288]C
| Domain | Evidence-informed interpretation | Limitation |
|---|---|---|
| Established ASCVD | Prior MI or PAD indicates high clinical risk and warrants interpretation alongside standard prognostic variables. [279][289] | Does not define a lipid concentration threshold. |
| Metabolic and visceral adiposity | BMI <30 kg/m² and absence of diabetes, hypertension, and hyperlipidemia do not exclude unfavorable visceral adiposity. [22]B2b | MRI-derived adipose-tissue cutoffs are not lipid-staging cutoffs. |
| Metabolic syndrome | Hyperlipidemia may contribute to cardiometabolic clustering; associations with mortality can vary by acute illness severity. [282] | Sepsis findings are not directly transferable to ambulatory care. |
| Pancreatitis | Hyperlipidemia is a recognized pancreatitis etiology or mixed-etiology context. [280] | No triglyceride threshold or lipid-specific severity estimate is reported. |
| Perioperative treatment | PCSK9 inhibitor or statin exposure within 90 days before surgery is relevant to postoperative risk assessment. [132]B2b | Comparative event estimates and treatment-based severity categories are unavailable in the supplied abstract. |
Acute and Initial Management
- ▸The supplied evidence does not establish a dedicated acute hyperlipidemia treatment threshold or comparative emergency lipid-lowering regimen. [294]
- ▸In suspected hyperlipidemic acute pancreatitis, assess inflammatory and metabolic severity and use monitored, syndrome-directed pancreatitis care. [294]
- ▸Treat acute coronary syndrome, stroke, ischemia, pancreatitis, and organ failure according to the presenting emergency; lipid management should be integrated into stabilization and secondary prevention. [159,291,292]
- ▸Medication effects, diabetes or insulin resistance, obesity, alcohol exposure, and recurrent weight gain should be reviewed as potential contributors to severe dyslipidemia. [60,254,261,292]
- ▸The L-arginine trial used 6 g/day for 2 months in lower-limb ischemia and does not support L-arginine for acute hyperlipidemia or hyperlipidemic pancreatitis. [290]
Scope of the available evidence
The supplied literature does not provide a dedicated randomized trial or consensus guideline defining acute treatment thresholds for primary hyperlipidemia. The most directly relevant acute presentation is hyperlipidemic acute pancreatitis (HLAP), for which a retrospective cohort of 113 patients evaluated the C-reactive-protein–triglyceride–glucose index (CTI) against severity classifications, but the available abstract does not report a triglyceride treatment threshold or compare acute lipid-lowering interventions. [294] Accordingly, initial management should be syndrome-directed and coordinated with emergency, gastroenterology, endocrinology, and intensive-care teams when organ dysfunction is present; specific drug selection and escalation should not be inferred from the studies listed here. [294]
Immediate assessment and triage
For a patient with markedly abnormal lipids and acute symptoms, first determine whether the presentation represents pancreatitis, acute coronary syndrome, ischemic stroke, acute limb ischemia, or another vascular emergency. The HLAP cohort specifically examined disease severity using the Revised Atlanta Classification and found that CTI was associated with severity, supporting assessment of both inflammation and insulin-resistance-related metabolic stress rather than relying on a lipid value alone. [294] In suspected acute coronary syndrome, rigorous secondary prevention is required after the acute event, although long-term lipid-lowering adherence remains challenging. [291] In suspected stroke, early neurological assessment and appropriate vascular imaging remain essential; studies supplied here address carotid-web diagnosis by digital subtraction angiography and outcomes after mechanical thrombectomy, but they do not establish hyperlipidemia-specific acute treatment. [232][159]B2b
Evaluate vital signs, hydration, mental status, abdominal and vascular findings, glucose, renal function, electrolytes, liver tests, pancreatic enzymes when pancreatitis is suspected, and a full lipid profile when clinically feasible. This broad assessment is justified by evidence linking lipid abnormalities with cardiometabolic, renal, inflammatory, and vascular conditions rather than by hyperlipidemia alone. [292][290][296]C Severe pregnancy-associated acute kidney injury was defined in one large cohort by dialysis initiation or a first recorded eGFR <15 mL/min/1.73 m²; this threshold belongs to acute kidney injury research and must not be repurposed as a lipid-treatment threshold. [158]B2b
Acute hypertriglyceridemia and suspected HLAP
When HLAP is suspected, prioritize standard acute pancreatitis supportive care, including monitored fluid and hemodynamic management, analgesia, antiemetic therapy when needed, nutritional planning, and early identification of organ failure; the supplied HLAP study supports severity stratification but does not test these interventions. [294] Search for precipitating or amplifying factors, including diabetes or insulin resistance, obesity, alcohol exposure, medication effects, and other secondary causes; the reviewed metabolic literature identifies hyperlipidemia as part of a broader metabolic-disease spectrum, while bariatric-surgery data show that previously resolved hyperlipidemia can recur with recurrent weight gain or other obesity-related disease. [60]D5[261]
Do not use L-arginine as an acute lipid-lowering treatment on the basis of the available evidence. A randomized, double-masked trial in 87 patients with atherosclerotic lower-limb ischemia evaluated oral L-arginine 6 g/day for 2 months for asymmetric dimethylarginine and homocysteine, with analyses by lipid-disorder subtype; this population, duration, and outcomes do not establish treatment for HLAP or acute cardiovascular events. [290] Similarly, evidence concerning Artemisia species is a systematic review of preclinical and clinical material across metabolic diseases and is insufficient to replace established acute care. [60]D5
Acute vascular events and transition to prevention
If an acute coronary syndrome occurs, initiate event-based secondary prevention and arrange continuation of lipid-lowering therapy after stabilization. The supplied adherence study identifies mental-health-related quality of life as associated with sustained lipid-lowering therapy adherence after ACS, supporting medication reconciliation, discharge education, assessment of depression and socioeconomic barriers, and early follow-up. [291] National U.S. data in adults with cardiovascular-kidney-metabolic syndrome evaluated treatment rates and control of hyperlipidemia from 2015–2023, emphasizing that treatment gaps persist in high-risk populations; these data describe practice patterns rather than an acute treatment protocol. [292]
Review medications that may worsen lipid metabolism. Bexarotene has a recognized metabolic-toxicity profile; in a propensity-matched real-world cohort of 2,242 exposed and 2,242 unexposed patients with mycosis fungoides, no significant increase in an adapted major-adverse-cardiovascular-event endpoint was observed, but this does not eliminate the need for lipid monitoring or define management of severe drug-induced dyslipidemia. [254] Cardiovascular-risk prediction models based on electronic health records and pharmacotherapy may assist longer-term risk stratification, but the Jordanian model was observational and should not determine emergency treatment. [257]
What not to extrapolate
Carotid-web treatment strategies, coronary CT angiography versus SPECT, PET-based coronary diagnostic models, vertigo stroke scores, cerebral vasospasm risk factors, fatigue outcomes in multiple sclerosis, orthopedic smart implants, transoral robotic-surgery risk scores, and complex aortic endarterectomy outcomes do not provide direct evidence for acute hyperlipidemia treatment. [232][233][157]B2a[293][295]C[268][251][283][296]C Their relevance is limited to reinforcing that acute lipid management must be individualized according to the presenting organ system, comorbidities, renal function, and procedural context. [232][233][157]B2a[293][295]C[268][251][283][296]C
Practical disposition
Admit or escalate monitoring when pancreatitis, ischemia, hemodynamic instability, altered mental status, renal failure, or other organ dysfunction is present; the supplied studies associate these clinical contexts with substantial risk but do not provide a validated hyperlipidemia-specific admission rule. [158]B2b[159]B2b[294] Once stabilized, document the lipid phenotype, investigate secondary causes, reconcile interacting medications, address diabetes, weight, diet, alcohol, and tobacco exposure, and establish a durable lipid-lowering and follow-up plan. [60]D5[261][292]
| Clinical situation | Initial priority | Evidence limitation |
|---|---|---|
| Suspected hyperlipidemic acute pancreatitis | Assess systemic severity, metabolic stress, and organ dysfunction; provide monitored pancreatitis care. [294] | No tested triglyceride threshold or acute lipid-lowering comparison is reported. [294] |
| Acute coronary syndrome | Stabilize the acute event and plan durable secondary prevention and lipid-lowering adherence support. [291] | Observational adherence data do not define an emergency regimen. [291] |
| Stroke or acute vascular ischemia | Perform urgent neurological or vascular assessment and treat the presenting emergency. [232][159]B2b[296]C | The cited studies do not establish hyperlipidemia-specific acute therapy. [232][159]B2b[296]C |
| Possible secondary or drug-induced dyslipidemia | Review diabetes, obesity, alcohol, medications, and recurrent weight gain. [60]D5[254][261][292] | Cited studies mainly address associations or long-term outcomes. [60]D5[254][261][292] |
Long-term Guideline-Directed Therapy
- ▸LDL-C lowering remains relevant in adults aged **≥75 years**; treatment decisions should be based on overall risk and tolerability rather than age alone. [164]
- ▸Bempedoic acid has phase 3 evidence in high-risk patients receiving maximal statins and in a statin-intolerant cardiovascular-outcomes population. [164]
- ▸Review calcium-channel-blocker and statin combinations for potential drug-drug interactions and adverse effects. [221]
- ▸Long-term lipid management should be integrated with cardiovascular-kidney-metabolic risk-factor treatment. [292]
- ▸Continue lipid surveillance after bariatric surgery, during bexarotene therapy, and in patients with complex cardiometabolic or vascular disease. [254,261,290]
Treatment objective and persistence
Long-term lipid management should be individualized according to baseline atherosclerotic cardiovascular disease (ASCVD) risk, comorbidities, tolerability, drug interactions, and the degree of low-density lipoprotein cholesterol (LDL-C) reduction required; the available evidence supports the principle that LDL-C lowering reduces major vascular events across age groups, including adults aged ≥75 years. [164]A1b Treatment should therefore be viewed as continuing risk reduction rather than a short-term intervention, with periodic reassessment of adherence, response, adverse effects, and changes in cardiovascular, renal, metabolic, or hepatic status. [164]A1b[292]
Statin-based therapy
Statins remain the foundational long-term pharmacologic approach when tolerated, because the phase 3 bempedoic-acid evidence specifically evaluated patients receiving maximal background statin therapy as well as patients unable to tolerate statins. [164]A1b The bempedoic-acid analysis included a "max-statins pool" comprising two 52-week placebo-controlled primary-hyperlipidemia studies and a separate "statin-intolerant pool" derived from a cardiovascular outcomes trial; efficacy assessments included LDL-C, non-high-density lipoprotein cholesterol, total cholesterol, and high-sensitivity C-reactive protein. [164]A1b
Statin selection should account for concomitant medicines. A 2026 systematic review and meta-analysis evaluated adverse effects, discontinuation, hospitalization, and all-cause mortality associated with combined calcium-channel-blocker (CCB) and statin use, reflecting clinically important potential drug-drug interactions with this common long-term combination. [221]A1a Patients receiving both therapies should have medication reconciliation and symptom review, with particular attention to new muscle symptoms or other suspected adverse effects; the cited review addresses the combination as a class-level safety question rather than establishing that every CCB-statin pairing is unsafe. [221]A1a
Statins may have biological effects beyond lipid lowering, although these should not replace LDL-C reduction as the primary treatment rationale. In a randomized, double-blind, 12-week study in healthy adults, simvastatin, pravastatin, and placebo were compared to test whether statin therapy influences aldosterone production, following prior observational and experimental findings suggesting lower aldosterone with statin exposure and a potentially greater effect with lipophilic statins. [297] This short-term mechanistic evidence does not establish a long-term indication for statins based on aldosterone modulation. [297]
Bempedoic acid and statin intolerance
Bempedoic acid is a relevant long-term option for high-risk patients who cannot tolerate statins or who require additional LDL-C lowering despite maximal tolerated statin therapy. [164]A1b In adults aged ≥75 years, the phase 3 post hoc analysis was specifically designed to characterize efficacy and safety according to concomitant statin exposure, including patients on maximal statins and patients in a statin-intolerant cardiovascular-outcomes population. [164]A1b Treatment decisions in older adults should therefore consider absolute cardiovascular risk, life expectancy, polypharmacy, baseline frailty, renal and hepatic status, and observed tolerability rather than age alone. [164]A1b
The available abstract reports evaluation of changes in LDL-C, non-HDL cholesterol, total cholesterol, and high-sensitivity C-reactive protein, together with safety outcomes, but does not provide the complete numerical results or detailed adverse-event rates in the supplied evidence. [164]A1b Accordingly, bempedoic acid should be presented as evidence-supported in high-risk older and statin-intolerant populations, while final drug selection and monitoring should follow the full product information and the patient’s clinical context. [164]A1b
Monitoring across cardiometabolic conditions
Hyperlipidemia commonly coexists with broader cardiometabolic disease. Contemporary U.S. data from adults with cardiovascular-kidney-metabolic syndrome stage ≥2 evaluated treatment rates and control of hypertension, diabetes, and hyperlipidemia from 2015 through 2023, underscoring the need to manage lipids alongside blood pressure, glycemia, kidney disease, obesity, and established CVD rather than in isolation. [292] Hyperlipidemia is also included among cardiometabolic risk factors in patients with chronic viral hepatitis and metabolic dysfunction-associated steatotic liver disease, and among metabolic comorbidities studied in schizophrenia. [168]C4[173]B2b
Lipid follow-up should be intensified when treatment or disease status changes. Patients with atherosclerotic lower-limb ischemia may have lipid-metabolism disorders alongside endothelial and vascular abnormalities, making comprehensive secondary prevention clinically relevant. [290] Bexarotene has a predictable metabolic-toxicity profile that can raise cardiovascular concerns in patients treated for mycosis fungoides, so lipid surveillance and coordination with the prescribing specialist are appropriate when this drug is used. [254] After metabolic and bariatric surgery, hyperlipidemia may initially resolve but can recur after weight regain or over longer follow-up, supporting continued surveillance rather than automatic discontinuation of lipid therapy after an early improvement. [261]
Practical long-term approach
Continue the maximally tolerated statin when possible; when LDL-C lowering remains inadequate or statins are not tolerated, consider evidence-supported nonstatin therapy such as bempedoic acid in appropriate high-risk patients, including those aged ≥75 years. [164]A1b Reassess lipid response and treatment tolerance after initiation or modification, then periodically during maintenance; review CCB co-prescription and other interacting medicines at each medication review. [221]A1a Integrate lipid treatment with management of the patient’s complete cardiovascular-kidney-metabolic risk profile and reassess therapy after major weight change, new liver or kidney disease, cancer therapy, or recurrent vascular events. [168]C4[254][261][292]
| Clinical situation | Long-term management implication |
|---|---|
| Statin tolerated | Continue the maximally tolerated statin and assess lipid response periodically. [164]A1b |
| Inadequate response despite maximal statin exposure | Consider additional therapy such as bempedoic acid in an appropriate high-risk patient. [164]A1b |
| Statin intolerance | Consider bempedoic acid as an evidence-supported option in suitable high-risk patients. [164]A1b |
| Age ≥75 years | Do not use age alone to withhold therapy; balance risk, benefit, polypharmacy, frailty, and tolerability. [164]A1b |
| Concomitant CCB therapy | Reconcile medicines and monitor for suspected adverse effects or interaction-related problems. [221]A1a |
| Major metabolic or treatment change | Repeat lipid assessment and reconsider the long-term regimen. [168]C4[254][261][292] |
Interventional and Device Therapy
- ▸PCI and drug-eluting stents treat coronary obstruction or ACS, not the underlying hyperlipidemia; lipid-lowering therapy remains necessary for secondary prevention. [179][181][183]
- ▸The SHEAR-STENT randomized study used OCT and computational-fluid-dynamics WSS analysis to evaluate 12-month neointimal healing in 86 PCI patients. [179]
- ▸cQFR was investigated as a post-primary-PCI marker of abnormal microvascular perfusion in a diagnostic cohort of 186 STEMI patients. [300]
- ▸WMT was associated with restoration of ILC3-related immune and metabolic signals in hyperlipidemia, but remains investigational. [299]
- ▸Coronary calcium scoring may assist cardiovascular-risk assessment in lung-transplant recipients, but it is diagnostic rather than lipid-lowering. [276]
- ▸The supplied evidence does not support topical oxygen therapy, cardiac rehabilitation, CRT-D, AI-ECG, diabetic-macular-edema assessment, or transplant-diabetes studies as treatments for hyperlipidemia. [187][180][301][302][182]
Scope and role
Interventional and device-based treatment does not replace lipid-lowering therapy for hyperlipidemia; it is primarily used to treat established atherosclerotic disease or its complications. The supplied evidence is heterogeneous and includes coronary intervention, vascular-flow assessment, transplant-associated cardiovascular care, microbiota-based treatment, and experimental metabolic interventions. Accordingly, most findings should be interpreted as adjunctive or investigational rather than as established treatments for dyslipidemia.
Percutaneous coronary intervention and stent therapy
Percutaneous coronary intervention (PCI) is a revascularization procedure for selected coronary lesions and acute coronary syndromes, not a treatment that corrects the underlying lipid disorder. Drug-eluting stents remain a central PCI technology in acute coronary syndrome (ACS), and a prospective single-center cohort followed patients treated with rapamycin-eluting or everolimus-eluting stents for 5–7 years to compare long-term safety, effectiveness, and cost; the supplied abstract does not report the comparative outcome results. [183]B2b In patients with non-ST-elevation ACS undergoing PCI, the CHIP Score was evaluated in a retrospective cohort of 348 patients as a predictor of post-discharge major adverse cardiac or cerebrovascular events, but this was a risk-validation study rather than a lipid-treatment trial. [181]B2b
The SHEAR-STENT randomized prospective study enrolled 86 patients undergoing PCI in angulated coronary arteries and compared Xience Xpedition everolimus-eluting stents with Resolute Integrity/Onyx zotarolimus-eluting stents. Serial optical coherence tomography (OCT) and computational-fluid-dynamics modeling were used to relate post-stent wall shear stress (WSS) to strut-, frame-, and patient-level neointimal thickness at 12 months. [179]A1b This study addresses vascular-healing mechanisms and device performance; it does not establish a cholesterol-lowering effect or demonstrate superiority of either stent for prevention of hyperlipidemia-related events. [179]A1b
Quantitative flow assessment may help characterize residual ischemic physiology after intervention. In patients with ST-segment-elevation myocardial infarction treated with successful primary PCI, contrast-flow quantitative flow ratio (cQFR) was studied in relation to abnormal microvascular perfusion using myocardial contrast perfusion echocardiography; the diagnostic cohort included 186 patients. [300] cQFR is therefore a potential post-PCI assessment tool, but the available evidence does not show that it modifies lipid levels or substitutes for intensive secondary prevention. [300]
Cardiovascular risk assessment in transplant populations
Coronary artery calcium scoring from non-gated, non-contrast computed tomography was evaluated in lung-transplant recipients without prior coronary revascularization as a predictor of obstructive coronary disease and major adverse cardiovascular events, defined as myocardial infarction, ischemic stroke, or all-cause death. [276] This supports coronary-risk stratification before or around transplantation, but it is diagnostic rather than lipid-lowering therapy. [276] A national inpatient analysis of PCI hospitalizations compared liver-transplant recipients with non-transplant patients using propensity-score matching; it examined in-hospital mortality and reflects procedural outcomes, not treatment of hyperlipidemia itself. [305]
Metabolic and microbiota-directed interventions
Washed microbiota transplantation (WMT) is an investigational biological intervention rather than a device-based treatment. In a prospective cohort of hyperlipidemia patients not receiving lipid-lowering medication, WMT was associated with restoration of circulating group 3 innate lymphoid cells (ILC3s), integrin-α4-positive ILC3s, and plasma interleukin-22, which were reduced in hyperlipidemia; microbial and plasma-metabolite changes were also assessed. [299] A hyperlipidemic mouse model was used to investigate whether healthy microbiota promote hepatic ILC3 homing through integrin α4. [299] These findings are mechanistically promising but do not establish WMT as a standard clinical lipid-lowering intervention. [299]
GLP-1 agonists may be used for weight and metabolic management after liver transplantation. In a retrospective cohort of 368 liver-transplant recipients, 73 (19.8%) received a GLP-1 analogue after transplantation; the study compared weight trajectory, comorbidities, and post-transplant outcomes with nonusers. [306] The supplied evidence does not establish a specific LDL-cholesterol reduction, cardiovascular-event benefit, or indication for GLP-1 therapy solely because hyperlipidemia is present. [306]
Adjunctive risk-factor management and experimental therapies
Statin therapy remains relevant to cardiovascular prevention in chronic kidney disease (CKD). A retrospective Swedish cohort evaluated adults aged 50–89 years with repeated estimated glomerular filtration rate values below 60 mL/min/1.73 m², without prior cardiovascular disease, diabetes, dialysis, transplantation, or another statin indication, and examined the association between primary-prevention statin use and all-cause mortality. [303] This evidence concerns preventive pharmacotherapy, not an interventional device, and observational associations should not be interpreted as proof of causation. [303]
Several supplied studies are not applicable to interventional treatment of hyperlipidemia. Everolimus pharmacokinetic monitoring in kidney-transplant recipients examined exposure, proteinuria, and de novo hyperlipidemia under tacrolimus-based therapy, indicating that immunosuppressive management may intersect with lipid abnormalities. [304] Cardiometabolic risk factors, including hyperlipidemia, were studied as predictors of recompensation and survival in alcohol-associated liver disease evaluated for early transplantation. [189]B2b Hepatic steatosis after kidney transplantation was assessed in 127 recipients, with 44 (30.1%) developing de novo steatosis. [275] Epicardial adipose tissue was evaluated in 138 STEMI patients after PCI as a prognostic and disease-severity marker. [307] Muscle-derived ANXA2 was investigated in experimental models of hepatic steatosis, while cinnamaldehyde was studied in cell and high-fat-diet models through SIRT1/FOXO1-related autophagy and gut-microbiota mechanisms; neither study provides clinical device or interventional evidence for hyperlipidemia treatment. [185]D5[186]D5
Topical oxygen therapy was retrospectively evaluated for refractory venous leg ulcers in 31 patients with 32 extremities, and cardiac rehabilitation was retrospectively examined for atrial-fibrillation recurrence after pulmonary-vein isolation; neither intervention directly treats hyperlipidemia. [187]C4[180]B2b AI-ECG age was studied retrospectively as a predictor of survival after CRT-D implantation, and kidney function was studied in relation to diabetic macular edema; these findings likewise do not provide lipid-lowering or hyperlipidemia-device evidence. [301][302] Lung-transplant recipients were also studied for post-transplant diabetes risk, which is relevant to metabolic risk but not a treatment for dyslipidemia. [182]B2b
Practical interpretation
For patients with hyperlipidemia and established coronary disease, PCI and drug-eluting stents should be viewed as treatment for obstructive or acute coronary disease, followed by comprehensive secondary prevention and lipid-lowering medication. [179]A1b[181]B2b[183]B2b WSS/OCT and cQFR may refine assessment of stent healing or residual perfusion, whereas calcium scoring may support transplant-related coronary-risk stratification. [179]A1b[276][300] WMT, GLP-1 agonists for transplant-associated metabolic disease, and microbiota- or pathway-directed approaches remain investigational or context-specific on the supplied evidence. [299][306][185]D5[186]D5
| Intervention or technology | Evidence and application | Role in hyperlipidemia |
|---|---|---|
| PCI and drug-eluting stents | ACS treatment; rapamycin- versus everolimus-eluting stents studied over 5–7 years. [183]B2b | Treats coronary disease; does not lower lipids. |
| OCT and WSS modeling | Randomized study of 86 patients with 12-month neointimal-healing assessment. [179]A1b | Device-healing research. |
| cQFR | Evaluated against microvascular-perfusion abnormalities after primary PCI in 186 STEMI patients. [300] | Post-PCI diagnostic assessment. |
| Coronary calcium scoring | Non-gated CT calcium scores assessed in lung-transplant recipients. [276] | Risk stratification, not treatment. |
| WMT | Prospective, medication-free hyperlipidemia cohort with ILC3, IL-22, microbiome, and metabolite assessment. [299] | Investigational metabolic intervention. |
| GLP-1 agonists | Used in 73 of 368 liver-transplant recipients. [306] | Context-specific weight/metabolic therapy; not proven lipid therapy. |
History and Evolution of Treatment
- ▸Contemporary hyperlipidemia management is increasingly risk-based and individualized rather than driven by lipid values alone. [164][308]
- ▸Statin research now evaluates treatment intensity, uncommon safety outcomes, and persistence with therapy. [291][312]
- ▸Bempedoic acid has been studied in patients aged **≥75 years** and in patients with differing statin exposure, including statin intolerance. [164]
- ▸MHT evidence reinforces the need to interpret lipids together with blood pressure, glucose, and metabolic syndrome. [308]
- ▸L-arginine, HDL-C, carotid plaque, and other biomarker or imaging studies do not replace evidence-based LDL-C-lowering treatment. [290][310][244]
From lipid measurement to risk-based management
The treatment of hyperlipidemia has evolved from addressing an isolated laboratory abnormality to integrating lipid concentrations with global cardiovascular risk, comorbidity, treatment tolerance, and long-term adherence. The supplied evidence reflects this modern, individualized phase rather than providing primary historical evidence for the earliest dietary, bile-acid sequestrant, niacin, fibrate, or statin-era milestones. Current research continues to treat low-density lipoprotein cholesterol (LDL-C) reduction as a central strategy for preventing major vascular events across age groups. [164]A1b
Statins and treatment intensity
Statins remain a foundational treatment class in the contemporary evidence base, but recent research has expanded evaluation beyond LDL-C lowering to include intensity-specific safety and implementation. A nationwide, propensity-score-matched TriNetX cohort compared high-, medium-, and low-intensity statin initiators with proton-pump-inhibitor users and an unexposed cohort among patients with hyperlipidemia; patients with previous uveitis or fibrate exposure were excluded, and the primary outcome was incident noninfectious uveitis over 5 years. [312] This design illustrates the current evolution toward evaluating uncommon extra-cardiovascular outcomes and comparing treatment intensity rather than assuming that higher intensity is uniformly preferable. [312]
The post-acute coronary syndrome (ACS) era has also shifted attention from prescription alone to persistence with lipid-lowering therapy. In ACS survivors enrolled in the TRACE-CORE cohort, investigators assessed psychological, socioeconomic, clinical, and mental-health factors associated with sustained lipid-lowering therapy adherence. [291] This supports an adherence-centered model in which treatment effectiveness depends not only on drug selection and LDL-C response but also on the patient’s ability to continue therapy over time. [291]
Nonstatin therapy and statin intolerance
Bempedoic acid represents an important later development in the treatment sequence for patients who require additional LDL-C lowering or cannot use statins adequately. A post hoc analysis of phase 3 placebo-controlled trials evaluated patients aged ≥75 years, including a pool receiving maximal background statin therapy and a statin-intolerant pool. Investigators assessed changes in LDL-C, non-high-density lipoprotein cholesterol, total cholesterol, and high-sensitivity C-reactive protein, together with safety. [164]A1b The study specifically addresses treatment personalization in very old adults and across differing degrees of statin exposure, extending the nonstatin evidence base beyond younger or conventionally treated populations. [164]A1b
Cardiometabolic context and hormonal therapy
Menopausal hormone therapy (MHT) is not a lipid-lowering treatment, but its cardiovascular effects illustrate why lipid management increasingly requires broader cardiometabolic assessment. A secondary analysis of two double-blind, placebo-controlled randomized trials compared conjugated equine estrogen (CEE) 0.625 mg/day, CEE plus medroxyprogesterone acetate (MPA) 2.5 mg/day, and placebo in postmenopausal women aged 50–79 years. Cardiometabolic status incorporated lipid profile, blood pressure, blood glucose, and metabolic syndrome, while coronary heart disease was defined as nonfatal myocardial infarction or coronary death. [308] The trials included 10,739 women in the CEE-alone study and 16,608 women in the CEE-plus-MPA study. [308] These data reinforce that lipid abnormalities should be interpreted alongside blood pressure, glycemia, and metabolic syndrome when estimating treatment benefit and cardiovascular harm. [308]
Adjunctive and mechanism-oriented approaches
Research has also examined therapies aimed at vascular biology rather than directly lowering atherogenic lipoproteins. In a randomized, double-masked, placebo-controlled trial of 87 patients with atherosclerotic lower-limb ischemia, oral L-arginine 6 g/day for 2 months was evaluated according to lipid-abnormality subtype, with asymmetric dimethylarginine and homocysteine as outcomes. [290] This approach remains adjunctive and biomarker-oriented; the study does not establish L-arginine as a substitute for evidence-based lipid-lowering therapy. [290]
Risk stratification and comorbidity-informed treatment
The modern treatment pathway increasingly uses associated disease to refine cardiovascular risk. A systematic review and meta-analysis of 37 studies evaluated carotid plaque detection and risk factors in obstructive sleep apnea syndrome, linking sleep-disordered breathing with atherosclerotic burden assessment. [310] A Swedish cohort of 2,201,446 women with singleton deliveries examined long-term peripheral artery disease risk after adverse pregnancy outcomes, supporting life-course risk assessment in women. [235] Hyperlipidemia was also included among predictors examined in a retrospective study of 1,968 patients with polycythemia vera or essential thrombocythemia, in which 404 second cancers occurred during a median 11.2-year follow-up. [260]
Other supplied studies provide contextual rather than treatment-direct evidence. Associations between attention-deficit/hyperactivity disorder and the “Life’s Crucial 9” cardiovascular risk factors highlight the importance of smoking, activity, diet, sleep, body mass index, lipids, glucose, blood pressure, and psychological health in young adults. [315] HDL-C, body roundness index, and diabetic retinopathy were examined cross-sectionally in 1,658 adults with diabetes, but this does not establish HDL-C modification as a treatment strategy. [244] Studies of carotid webs, ischemic-stroke degeneration, postoperative atrial fibrillation, recurrent jaw osteonecrosis, pregnancy-related vascular risk, shoulder repair, ocular surgery, and testosterone treatment do not provide evidence for changing hyperlipidemia therapy; they instead emphasize that treatment decisions should account for competing vascular, procedural, and medication-related risks. [232][298][62]B3b[311][255][309][313][314]
Current direction
The trajectory of treatment is therefore toward intensive but individualized LDL-C reduction, selective use of nonstatins such as bempedoic acid, systematic assessment of statin tolerability and adherence, and integration of lipid findings with the patient’s complete cardiometabolic and vascular profile. [164]A1b[291][308]
| Treatment or development | Population/design | Contribution to the treatment history |
|---|---|---|
| Statin intensity | Propensity-score-matched nationwide cohort of patients with hyperlipidemia; high-, medium-, and low-intensity statins compared with active and unexposed controls | Expands safety evaluation beyond LDL-C lowering and examines intensity-specific outcomes. [312] |
| Bempedoic acid | Phase 3 placebo-controlled studies in patients aged ≥75 years, including maximal-statin and statin-intolerant groups | Supports individualized nonstatin therapy according to age and statin exposure. [164]A1b |
| Long-term adherence | TRACE-CORE ACS survivor cohort | Demonstrates that sustained lipid-lowering benefit depends on psychological, socioeconomic, and clinical determinants of adherence. [291] |
| Cardiometabolic integration | Two randomized MHT trials including 27,347 participants overall | Shows why lipids should be assessed with blood pressure, glucose, and metabolic syndrome. [308] |
| Adjunctive vascular biology | Randomized trial of 87 patients with lower-limb ischemia; L-arginine 6 g/day for 2 months | Investigates vascular biomarkers but does not establish a replacement for lipid-lowering therapy. [290] |
Complications
- ▸The principal established clinical concern is atherosclerotic cardiovascular risk, with LDL-cholesterol lowering associated with fewer major vascular events across age groups. [164]
- ▸Severe hypertriglyceridemia is defined here as **>500 mg/dL**, while mixed hyperlipidemia is **150–499 mg/dL** in the plozasiran trials. [316]
- ▸Cardiometabolic comorbidity, including diabetes, hypertension, visceral adiposity, and metabolic syndrome, may amplify clinical risk and complicate interpretation of hyperlipidemia-associated outcomes. [22][168][173][220]
- ▸Pregnancy outcomes, cataract subtypes, and critical-illness mortality have been studied in association with hyperlipidemia, but the cited observational evidence does not prove causation. [121][220][320]
- ▸Lipid-lowering treatment requires surveillance for adverse effects and drug interactions, particularly with concomitant calcium-channel blockers or statins. [221]
Cardiovascular complications
Hyperlipidemia is clinically important because elevated atherogenic lipoproteins contribute to major vascular events; LDL-cholesterol reduction is associated with lower risk of such events across age groups, including adults aged ≥75 years in analyses of bempedoic acid trials. [164]A1b Cardiometabolic status—including lipid profile, blood pressure, blood glucose, and metabolic syndrome—may modify cardiovascular responses to oral menopausal hormone therapy; this was evaluated in two large randomized, placebo-controlled trials of conjugated equine estrogens with or without medroxyprogesterone in postmenopausal women aged 50–79 years. [308]
Hyperlipidemia may coexist with, and contribute to the burden of, coronary heart disease, myocardial infarction, and cardiovascular death, although the supplied evidence does not establish that hyperlipidemia alone caused each outcome. [308] In apolipoprotein E-deficient mice receiving a high-fat diet, experimentally induced chronic pain was investigated as a synergistic contributor to cardiac injury; the study measured left-ventricular ejection fraction and fractional shortening and examined the c-Jun N-terminal kinase 1/silent information regulator 1 signaling axis. [263] Because this was an animal study using 32 male mice, its findings should not be directly extrapolated to human complication rates. [263]
Cerebrovascular and peripheral arterial disease
Atherosclerotic vascular disease associated with dyslipidemia can manifest in the carotid and peripheral arterial beds. A Swedish cohort of 2,201,446 women evaluated long-term peripheral artery disease after adverse pregnancy outcomes, highlighting pregnancy history as an additional vascular-risk marker rather than proving that hyperlipidemia was the causal exposure. [235] In a separate retrospective series of 296 patients with 349 common femoral artery lesions, stenting was used for symptomatic occlusive disease, including claudication, rest pain, ulceration, or gangrene; the study population had substantial comorbidity and does not quantify hyperlipidemia-specific risk. [319]
Carotid webs are a distinct structural arterial abnormality associated with ischemic stroke and recurrent ipsilateral ischemic events; a digital-subtraction-angiography study described clinical features, treatment, and follow-up in 48 patients. [232] The available abstract does not demonstrate that hyperlipidemia causes carotid webs. [232] Similarly, perioperative outcomes after carotid endarterectomy were compared for dual antiplatelet therapy versus aspirin monotherapy in patients with carotid stenosis, with major bleeding and major adverse cardiovascular events as outcomes; these findings concern treatment strategy rather than a direct complication rate from hyperlipidemia. [79]B2b
Metabolic, hepatic, and critical-illness complications
Hyperlipidemia commonly occurs within broader cardiometabolic disease. In UK Biobank participants classified as metabolically healthy, non-obese—defined in the study by BMI <30 kg/m², absence of diabetes or hypertension, and absence of hyperlipidemia—MRI-derived visceral adipose tissue and subcutaneous adipose tissue were used to identify unfavorable fat distribution that may not be captured by BMI or waist circumference. [22]B2b In chronic viral hepatitis, metabolic dysfunction-associated steatotic liver disease was defined using a hepatic steatosis index of ≥36 plus at least one cardiometabolic risk factor, including hyperlipidemia; the registry evaluated fibrosis, symptoms, fatigue, quality of life, and work productivity. [168]C4
Among 3,229 critically ill patients with hyperlipidemia in the MIMIC-IV database, hemoglobin glycation index was examined in relation to in-hospital and 28-day mortality. [220]C4 This retrospective association does not establish that hyperlipidemia itself caused mortality, but it supports the importance of glycemic-metabolic status when assessing prognosis in hospitalized patients with hyperlipidemia. [220]C4 In schizophrenia, dyslipidemia, central adiposity, insulin resistance, and hypertension were analyzed as cumulative metabolic comorbidities associated with cardiovascular disease, related mortality, and increased medical costs. [173]B2b
Pregnancy, ocular, and other reported associations
In a retrospective cohort of 3,526 pregnant women with late-pregnancy hyperlipidemia, investigators compared those with and without gestational diabetes mellitus and assessed adverse maternal and neonatal outcomes. [320]C The evidence supports concern about combined metabolic burden during pregnancy but does not establish causality because the study was observational. [320]C
A clinic-based cross-sectional study of 384 patients with age-related cataract examined subtype-specific associations between hyperlipidemia and cortical, nuclear, and posterior subcapsular cataract; the study addressed a relationship described as controversial and therefore should be interpreted as associative rather than causal. [121]C4 Osteonecrosis is a severe complication of systemic lupus erythematosus, and a meta-analysis of 64 studies evaluated related risk factors; the supplied evidence does not identify hyperlipidemia as a confirmed cause of osteonecrosis. [249]
Treatment-related complications and disease recurrence
Lipid-lowering therapy can itself produce adverse effects. A systematic review and meta-analysis evaluated adverse effects, treatment discontinuation, hospitalization, and all-cause mortality when statins were combined with calcium-channel blockers, reflecting potential drug–drug interaction risk. [221]A1a Bempedoic acid studies in older adults assessed LDL-cholesterol, non-HDL cholesterol, total cholesterol, high-sensitivity C-reactive protein, efficacy, and safety with or without background statin therapy. [164]A1b Plozasiran, an apolipoprotein C-III–targeted hepatocyte siRNA, produced sustained reductions in triglycerides and related atherogenic lipoproteins in open-label extensions involving severe hypertriglyceridemia (>500 mg/dL) and mixed hyperlipidemia (150–499 mg/dL); it has been approved for familial chylomicronemia syndrome in the United States and subsequently Canada and China. [316]
After metabolic and bariatric surgery, previously remitted hyperlipidemia may recur along with other obesity-related conditions; a retrospective study examined recurrence after sleeve gastrectomy, Roux-en-Y gastric bypass, or duodenal switch in patients with at least 36 months of follow-up and at least 20% total weight loss. [261] Treatment and monitoring should therefore address both residual lipid risk and recurrence after apparent remission. [261] Medication-prescription interception data further indicate that outpatient prescription errors and potentially problematic prescriptions remain medication-safety concerns, although this study was not specific to lipid treatment. [317] Heterogeneous treatment effects across nine glucose-lowering drug classes in type 2 diabetes likewise emphasize that treatment response may vary across patient characteristics, but the study does not directly quantify hyperlipidemia complications. [318] Psychological symptoms and cumulative social disadvantage were associated with adverse cardiovascular-health risk factors in women of reproductive age, providing additional context for comprehensive cardiovascular risk assessment in patients with hyperlipidemia. [321]
Prognosis and Natural History
- ▸Hyperlipidemia is best viewed as part of an integrated cardiometabolic risk phenotype, with prognosis influenced by visceral adiposity, hypertension, dysglycemia, metabolic syndrome, and established vascular disease. [308] [322] [22]
- ▸MRI-based evidence in 36,831 UK Biobank participants linked body-composition traits with hyperlipidemia, myocardial infarction, cerebral infarction, hypertension, and type 2 diabetes, supporting risk assessment beyond BMI alone. [322]
- ▸In 22,040 metabolically healthy, non-obese adults, visceral adiposity was investigated as a marker of future cardiometabolic disease despite the absence of baseline **diabetes, hypertension, or hyperlipidemia**. [22]
- ▸Hyperlipidemia may recur after bariatric-surgery remission, particularly because recurrence was specifically assessed after at least **36 months** of follow-up and at least **20% total weight loss**. [261]
- ▸Retinal safety and vascular-outcome surveillance has been studied with different statin intensities and PCSK9 inhibitors, but the supplied abstracts do not provide definitive effect estimates. [312] [324]
- ▸An apparent survival advantage associated with hyperlipidemia in sepsis is context-specific and must not be extrapolated to chronic cardiovascular prognosis. [282]
Overview
Hyperlipidemia is a chronic, multifactorial cardiometabolic condition whose long-term prognosis is determined less by the lipid measurement alone than by cumulative exposure to atherogenic lipoproteins and the presence of obesity, hypertension, dysglycemia, metabolic syndrome, smoking, established atherosclerotic disease, and other comorbidities. The supplied 2026 evidence reinforces that lipid abnormalities frequently cluster with broader cardiometabolic risk rather than occurring in isolation. [308] [322] [22]B2b
Cardiovascular and cerebrovascular trajectory
The principal adverse natural-history concern is progression to atherosclerotic cardiovascular disease, including coronary heart disease, myocardial infarction, and cerebral infarction. In a longitudinal UK Biobank study of 36,831 adults aged 45–82 years, MRI-derived adiposity traits were evaluated in relation to type 2 diabetes, hypertension, hyperlipidemia, myocardial infarction, and cerebral infarction, emphasizing that visceral and ectopic fat may refine risk assessment beyond body-mass index. [322] In a prospective cohort of 22,040 metabolically healthy, non-obese participants, investigators specifically examined whether unfavorable visceral adiposity, including a high visceral-to-subcutaneous adipose-tissue ratio, identifies individuals who subsequently develop cardiometabolic disease despite the absence of baseline diabetes, hypertension, or hyperlipidemia. [22]B2b
These studies support a clinical model in which apparently low-risk patients may transition to hyperlipidemia or related vascular disease when adverse fat distribution and cardiometabolic risk accumulate. [322] [22]B2b The occupational cohort established among 25,597 eligible coal-industry workers within a larger 2023 examination population of 36,577 workers, with retrospective data from 2009–2022 and prospective follow-up beginning in May 2023, is designed to characterize the longitudinal burden and determinants of noncommunicable disease, including cardiometabolic conditions. [250]
Effect of cardiometabolic context
Randomized evidence from two placebo-controlled trials of menopausal hormone therapy included 27,347 women aged 50–79 years and assessed coronary heart disease according to lipid profile, blood pressure, blood glucose, and metabolic syndrome status. [308] The study evaluated conjugated equine estrogen alone in women with prior hysterectomy and conjugated equine estrogen plus medroxyprogesterone acetate in women with an intact uterus. [308] Its prognostic relevance is that the cardiovascular consequences of an intervention may vary according to baseline cardiometabolic status; therefore, hyperlipidemia should be interpreted as one component of an integrated risk phenotype rather than as an isolated laboratory abnormality. [308]
In acute illness, the association between hyperlipidemia and outcome may differ from its chronic atherosclerotic meaning. A multicenter cohort of 2,973 adults with sepsis found metabolic syndrome in 1,309 patients (44.0%) and evaluated whether mortality associations varied by disease severity and individual metabolic-syndrome components, including hyperlipidemia. [282] The reported title describes a severity-dependent survival advantage associated with metabolic syndrome that was driven by overweight and hyperlipidemia; this finding should not be interpreted as evidence that hyperlipidemia is protective in the general population, because it arose from a retrospective, hospitalized sepsis cohort and may reflect selection, reverse-causation, or acute-phase effects. [282]
Treatment-related prognosis
Lipid lowering is generally used to reduce future vascular risk, but the supplied references also address longer-term safety signals. In a systematic review and meta-analysis of six high-quality and one moderate-quality study, statin therapy was evaluated after arthroscopic rotator-cuff repair because of historical concerns about muscle and tendon toxicity; the review specifically assessed tendon healing, revision surgery, and patient-reported outcomes. [212]A1a The available abstract states that clinical results had been mixed and that preclinical data suggested anti-inflammatory and antifibrotic effects, but it does not provide the pooled numerical estimates in the supplied material. [212]A1a
Among patients with hyperlipidemia, a propensity-matched TriNetX study evaluated the 5-year risk of incident noninfectious uveitis according to high-, medium-, or low-intensity statin therapy, using proton-pump-inhibitor users and untreated controls and excluding patients with previous uveitis or fibrate exposure. [312] A separate comparative cohort examined whether PCSK9 inhibitors were associated with retinal artery or retinal vein occlusion in patients with hyperlipidemia defined by LDL cholesterol ≥130 mg/dL and total cholesterol ≥220 mg/dL. [324] The supplied abstracts do not report the effect estimates, so these studies currently indicate areas of safety and outcome surveillance rather than establishing a definitive causal prognosis. [312] [324]
Recurrence and comorbidity burden
Hyperlipidemia may remit after substantial weight loss but can recur. A retrospective bariatric-surgery study included patients who achieved at least 20% total weight loss, had at least 36 months of follow-up, and initially entered remission from obesity-related conditions including hyperlipidemia; it specifically investigated recurrence after sleeve gastrectomy, Roux-en-Y gastric bypass, or duodenal switch. [261] This supports continued long-term lipid surveillance even after metabolic improvement. [261]
Cardiometabolic disease also modifies outcomes outside vascular medicine. In real-world cohorts of knee osteoarthritis treated with intra-articular hyaluronic acid, and in studies of platelet-rich plasma response, hyperlipidemia was considered part of the lifestyle-related or cardiometabolic disease burden that may influence treatment response and clinically relevant outcomes. [258] [323] These associations are prognostic modifiers rather than evidence that hyperlipidemia directly causes treatment failure. [258] [323]
Practical prognostic interpretation
Prognosis is most unfavorable when hyperlipidemia is persistent, accompanied by visceral adiposity or metabolic syndrome, or occurs alongside established vascular disease and other major risk factors. [308] [322] [22]B2b Risk assessment should therefore be longitudinal, incorporating lipid trends, treatment adherence, weight and fat distribution, blood pressure, glucose status, and evidence of coronary, cerebral, or peripheral arterial disease. [250] [322] [308] The current supplied evidence does not provide a single universal time-to-event estimate for untreated hyperlipidemia, and several newer treatment-safety studies report no numerical outcomes in the available abstracts. [212]A1a [312] [324]
| Evidence area | Population or threshold | Prognostic implication |
|---|---|---|
| Adiposity and vascular risk | 36,831 UK Biobank participants, age 45–82 years; MRI-derived body composition | Visceral and ectopic fat may improve prediction of hyperlipidemia, myocardial infarction, cerebral infarction, hypertension, and type 2 diabetes beyond BMI. [322] |
| “Metabolically healthy” status | 22,040 participants; BMI <30 kg/m² and no diabetes, hypertension, or hyperlipidemia at baseline | Unfavorable visceral adiposity may precede incident cardiometabolic disease. [22]B2b |
| Bariatric-surgery remission | ≥20% total weight loss and ≥36 months of follow-up | Hyperlipidemia can recur after initial remission, supporting long-term monitoring. [261] |
| PCSK9 inhibitor outcome study | Hyperlipidemia defined as LDL cholesterol ≥130 mg/dL and total cholesterol ≥220 mg/dL | Retinal artery and vein occlusion outcomes were evaluated, but numerical estimates were not available in the supplied abstract. [324] |
| Statin safety surveillance | High-, medium-, and low-intensity statins; 5-year follow-up for noninfectious uveitis | The association with uveitis remains incompletely defined from the supplied abstract. [312] |
Special Populations and Prevention
- ▸Adults aged **≥75 years** were specifically evaluated in phase 3 bempedoic-acid analyses stratified by statin exposure, with LDL-C efficacy and safety assessed. [164]
- ▸For secondary stroke prevention, the cited framework used LDL-C **<70 mg/dL**, blood pressure **<130/80 mm Hg**, and hemoglobin A1c **<6.5%** without diabetes or **<7.0%** with diabetes, together with nonsmoking. [245]
- ▸Pregnancy-related stroke was estimated at approximately **30 per 100,000 pregnancies** and was associated with risk factors including hypertension, diabetes, and hyperlipidemia. [224]
- ▸GDM and adverse pregnancy outcomes identify patients who may benefit from structured postpartum cardiovascular, kidney, metabolic, and vascular-risk follow-up. [252][327][235]
- ▸In CKD, integrated management of eight lifestyle factors was studied for MASLD-risk mitigation, supporting comprehensive rather than lipid-only prevention. [225]
- ▸Polypharmacy review is essential in older adults with heart failure, particularly when medication burden reaches **≥15 drugs**. [134]
Older adults
Lipid lowering remains relevant across age groups because LDL-C reduction is associated with lower major vascular-event risk, including in older adults. A post hoc analysis of phase 3 placebo-controlled bempedoic-acid studies specifically evaluated adults aged ≥75 years, including patients receiving maximal background statin therapy and a cardiovascular-outcomes cohort with statin intolerance. Outcomes assessed included LDL-C, non-HDL-C, total cholesterol, high-sensitivity C-reactive protein, and safety over follow-up periods that included 52 weeks in the primary-hyperlipidemia studies. [164]A1b Treatment decisions in this age group should therefore account for baseline cardiovascular risk, statin exposure or intolerance, comorbidity, polypharmacy, renal function, functional status, and patient preferences; however, the supplied evidence does not establish a universal treatment threshold or target for every older adult. [164]A1b[134]B2b
Polypharmacy is common in older adults with heart failure, and a multicenter cohort of 7,361 patients aged ≥65 years classified medication burden as 0–4 drugs, 5–9 drugs, 10–14 drugs, or ≥15 drugs; potentially inappropriate medications were assessed using the 2019 Beers Criteria. [134]B2b Hyperlipidemia should consequently be reviewed within the complete medication regimen, with attention to adherence, duplicate therapy, drug interactions, renal or hepatic considerations, and treatment burden. The study evaluated medication burden and adverse outcomes in elderly heart-failure patients rather than lipid-specific regimens, so it supports medication reconciliation but not a specific lipid-lowering sequence. [134]B2b
Cardiovascular-kidney-metabolic risk
Hyperlipidemia is one component of cardiovascular-kidney-metabolic (CKM) syndrome. National U.S. data from 2015–2023 evaluated treatment rates and control of hyperlipidemia, hypertension, and diabetes among adults with CKM stage 2 or higher, highlighting the importance of coordinated risk-factor management rather than isolated lipid treatment. [292] Among U.S. adults with prior stroke, guideline-based risk-factor control was defined using LDL-C <70 mg/dL, blood pressure <130/80 mm Hg, hemoglobin A1c <6.5% without diabetes or <7.0% with diabetes, and nonsmoking; trends were assessed from 1999–2023. [245] These thresholds describe the study’s prevention framework and should not be generalized beyond the populations and guideline definitions used in those analyses. [245]
Chronic kidney disease (CKD) is a high-risk context in which lifestyle and metabolic risk deserve particular attention. In a prospective UK Biobank cohort comprising 9,877 individuals with CKD and 421,043 non-CKD controls, management of eight lifestyle factors—body mass index, diet, physical activity, alcohol use, smoking, social connection, sedentary behavior, and sleep duration—was examined in relation to metabolic dysfunction-associated steatotic liver disease (MASLD) risk. [225]B2b The study supports integrated lifestyle counseling for cardiometabolic risk reduction in CKD, although it does not demonstrate that lifestyle management alone lowers LDL-C or cardiovascular events. [225]B2b
Pregnancy, gestational diabetes, and postpartum prevention
Pregnancy requires individualized risk assessment because hyperlipidemia may coexist with gestational diabetes mellitus (GDM) and other cardiometabolic risk factors. A retrospective cohort of 3,526 singleton pregnancies complicated by hyperlipidemia in late pregnancy compared 842 women with GDM with 2,684 without GDM for maternal and neonatal outcomes. [320]C Because this was an observational study, the reported associations should not be interpreted as proof that hyperlipidemia or GDM caused the outcomes, and the evidence supplied does not define a lipid-drug treatment strategy during pregnancy. [320]C
Pregnancy-related stroke occurs at approximately 30 per 100,000 pregnancies in the cited systematic review and meta-analysis and was reported as roughly three times more frequent than in the general young-adult population; hypertension, diabetes, and hyperlipidemia were identified among relevant risk factors. [224]A1a Prevention should therefore include recognition and management of modifiable vascular risks before conception, during pregnancy when appropriate, and after delivery, with treatment choices individualized to pregnancy status and specialist guidance. [224]A1a
GDM is also a marker of future maternal risk. A retrospective MarketScan cohort of commercially insured females aged 12–55 years without preexisting CKM disorders before delivery assessed incident postpartum cardiovascular, kidney, and metabolic disorders after a single delivery complicated by GDM. [252] Other contemporary cohorts found that adverse pregnancy outcomes were associated with development of short-term cardiovascular risk factors after delivery, [327] and a Swedish national cohort of 2,201,446 women followed through 2018 evaluated long-term peripheral artery disease risk after five major adverse pregnancy outcomes, including familial confounding through co-sibling analyses. [235] These findings support postpartum transition-of-care, cardiovascular-risk surveillance, and sustained lifestyle prevention after GDM or adverse pregnancy outcomes, although they do not establish lipid-specific screening intervals. [252][327][235]
Severe pregnancy-associated acute kidney injury (PrAKI) is an uncommon but potentially life-threatening complication. A U.S. electronic-health-record cohort of 4,094,111 pregnancies from 2012–2022 used a stringent definition: dialysis initiation or a first recorded estimated glomerular filtration rate <15 mL/min/1.73 m². [158]B2b Such kidney complications may increase long-term CKM complexity and reinforce the need for coordinated renal, metabolic, and cardiovascular follow-up, but the cited study did not test lipid-lowering interventions. [158]B2b
Other relevant populations and prevention signals
In a cohort of 39,244 deliveries, early-pregnancy uterine fibroids were identified in 674 women, and analyses adjusted for hyperlipidemia, obesity, maternal age, BMI, parity, and other factors when evaluating adverse pregnancy outcomes. [214]C4 This adjustment indicates that hyperlipidemia was considered a potential confounder; it does not establish an independent causal relationship between hyperlipidemia and fibroid-related outcomes. [214]C4
Among adults with age-related cataract, a clinic-based cross-sectional study of 384 participants examined associations between lipid-related biochemical measures and cortical, nuclear, and posterior-subcapsular cataract severity. [121]C4 These findings are hypothesis-generating and do not justify lipid treatment solely for cataract prevention. [121]C4 In older adults undergoing carotid Doppler ultrasonography, the C-reactive-protein–albumin–lymphocyte (CALLY) index was evaluated alongside carotid stenosis, intima-media thickness, hyperlipidemia, hypertension, diabetes, smoking, and age, including comparisons above and below 65 years. [325] Because the study was retrospective and observational, CALLY should not replace established lipid and vascular-risk assessment. [325]
Cardiac amyloidosis and coronary artery disease may coexist in older patients: a retrospective series of 255 patients with cardiac amyloidosis identified 81 with significant CAD and assessed mortality and cardiac magnetic-resonance features. [326] Lipid management should therefore be integrated with, rather than substituted for, evaluation of suspected CAD and amyloidosis. [326] Additional prevention data from former athletes and their families aged ≥50 years examined physical activity, tobacco use, obesity, hypertension, diabetes, alcohol intake, and hyperlipidemia in relation to structural heart abnormalities. [331] Finally, a population-based Fujian eye study of 8,211 adults aged >50 years evaluated uncorrected presbyopia and associated factors; it did not establish a lipid-specific intervention. [330]C
Practical prevention approach
Use a whole-person strategy: confirm the lipid phenotype and overall vascular risk; assess diabetes, hypertension, CKD, obesity, smoking, alcohol use, diet, physical activity, and sedentary behavior; review pregnancy or postpartum status; reconcile medications in older adults; and arrange longitudinal follow-up after GDM, adverse pregnancy outcomes, stroke, or kidney injury. [164]A1b[134]B2b[224]A1a[225]B2b[245][252][327][235][158]B2b The supplied studies support risk-factor integration and targeted follow-up, but most are observational or post hoc and therefore do not replace prospective treatment guidelines. [164]A1b[214]C4[225]B2b[252][325][326][330]C[331]
| Population or context | Evidence-informed consideration |
|---|---|
| Adults aged ≥75 years | Bempedoic-acid phase 3 analyses assessed LDL-C, non-HDL-C, total cholesterol, hs-CRP, and safety by statin exposure. [164]A1b |
| Prior stroke | The cited prevention framework used LDL-C <70 mg/dL, BP <130/80 mm Hg, HbA1c <6.5% without diabetes or <7.0% with diabetes, and nonsmoking. [245] |
| CKD | Integrated management of BMI, diet, activity, alcohol, smoking, social connection, sedentary behavior, and sleep was associated with evaluation of MASLD risk. [225]B2b |
| Pregnancy or postpartum period | Hyperlipidemia, GDM, adverse pregnancy outcomes, and pregnancy-related stroke warrant coordinated vascular and cardiometabolic risk assessment; the supplied studies do not define pregnancy-specific lipid-drug regimens. [224]A1a[320]C[252][327][235] |
| Older adults with heart failure | Medication burden and potentially inappropriate medications should be reviewed before intensifying therapy. [134]B2b |
References
- [1]
McCrindle BW, Urbina EM, Dennison BA et al.. “Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing.” Circulation (2007). PMID: 17377073 ↗
L1GUIDELINECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications - [2]
Pasupathy S, Air T, Dreyer RP et al.. “Systematic review of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries.” Circulation (2015). PMID: 25587100 ↗
L2SR_OBSCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Prognosis and Natural History - [3]
Wiegman A, Peterson AL, Hegele RA et al.. “Efficacy and Safety of Inclisiran in Adolescents With Genetically Confirmed Homozygous Familial Hypercholesterolemia: Results From the Double-Blind, Placebo-Controlled Part of the ORION-13 Randomized Trial.” Circulation (2025). PMID: 40391436 ↗
L1RCTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications - [4]
Cooper LA, Marsteller JA, Carson KA et al.. “Equitable Care for Hypertension: Blood Pressure and Patient-Reported Outcomes of the RICH LIFE Cluster Randomized Trial.” Circulation (2024). PMID: 39008556 ↗
L1RCTCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment - [5]
Paramsothy P, Knopp RH, Bertoni AG et al.. “Association of combinations of lipid parameters with carotid intima-media thickness and coronary artery calcium in the MESA (Multi-Ethnic Study of Atherosclerosis).” Journal of the American College of Cardiology (2010). PMID: 20846602 ↗
L2TRIAL_NONRANDOMCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup - [6]
Stone GW, Selker HP, Thiele H et al.. “Relationship Between Infarct Size and Outcomes Following Primary PCI: Patient-Level Analysis From 10 Randomized Trials.” Journal of the American College of Cardiology (2016). PMID: 27056772 ↗
L1SR_OBSCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Prognosis and Natural History - [7]
Cho L, Davis M, Elgendy I et al.. “Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women: JACC State-of-the-Art Review.” Journal of the American College of Cardiology (2020). PMID: 32439010 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Long-term Guideline-Directed Therapy, Complications, Special Populations and Prevention - [8]
Ridker PM, Lei L, Louie MJ et al.. “Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin Intolerance.” Circulation (2023). PMID: 37929602 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy, Complications - [9]
Boyer TM, Barrett RB, Xiong C et al.. “Hypertensive Disorders of Pregnancy and Premature Cardiovascular Disease in a Diverse Cohort of Young US Women.” Circulation (2025). PMID: 41697979 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Special Populations and Prevention - [10]
Mosley JD, Benson MD, Smith JG et al.. “Probing the Virtual Proteome to Identify Novel Disease Biomarkers.” Circulation (2018). PMID: 30571344 ↗
L3OTHERCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup - [11]
Jayaraman R, Reinier K, Nair S et al.. “Risk Factors of Sudden Cardiac Death in the Young: Multiple-Year Community-Wide Assessment.” Circulation (2017). PMID: 29269388 ↗
L4OTHERCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, Prognosis and Natural History - [12]
Covani M, Niccoli G, Fujimoto D et al.. “Plaque Vulnerability and Cardiovascular Risk Factor Burden in Acute Coronary Syndrome: An Optical Coherence Tomography Analysis.” Journal of the American College of Cardiology (2025). PMID: 40634017 ↗
L4OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Complications - [13]
Elgendy IY, Gad MM, Mahmoud AN et al.. “Acute Stroke During Pregnancy and Puerperium.” Journal of the American College of Cardiology (2020). PMID: 31948647 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Prognosis and Natural History, Special Populations and Prevention - [14]
Krishnan P, Farhan S, Schneider P et al.. “Determinants of Drug-Coated Balloon Failure in Patients Undergoing Femoropopliteal Arterial Intervention.” Journal of the American College of Cardiology (2022). PMID: 36137674 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy - [15]
DeFilippis EM, Singh A, Divakaran S et al.. “Cocaine and Marijuana Use Among Young Adults With Myocardial Infarction.” Journal of the American College of Cardiology (2018). PMID: 29535062 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Prognosis and Natural History - [16]
Ahn JM, Lee KH, Yoo SY et al.. “Prognosis of Variant Angina Manifesting as Aborted Sudden Cardiac Death.” Journal of the American College of Cardiology (2016). PMID: 27386766 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Prognosis and Natural History - [17]
Martin SS, Niles JK, Kaufman HW et al.. “Lipid distributions in the Global Diagnostics Network across five continents.” European heart journal (2023). PMID: 37392135 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Long-term Guideline-Directed Therapy - [18]
Ditkofsky N, Hanna T. “Images in Clinical Medicine. Spontaneous Retropharyngeal Hematoma.” The New England journal of medicine (2016). PMID: 26789902 ↗
L4CASE_REPORTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management - [19]
Otto CM, Newby DE, Hillis GS. “Calcific Aortic Stenosis: A Review.” JAMA (2024). PMID: 39527048 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Complications, Prognosis and Natural History - [20]
Tilg H, Petta S, Stefan N et al.. “Metabolic Dysfunction-Associated Steatotic Liver Disease in Adults: A Review.” JAMA (2026). PMID: 41212550 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications - [21]
McFarland R, Hyslop LA, Feeney C et al.. “Mitochondrial Donation in a Reproductive Care Pathway for mtDNA Disease.” The New England journal of medicine (2025). PMID: 40689593 ↗
L4OTHERCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications, Special Populations and Prevention - [22]
Bogner B, Jung M, Reisert M et al.. “Opportunistic screening for incident cardiometabolic disease in metabolically healthy non-obese individuals: a prospective cohort study.” Cardiovascular diabetology (2026). PMID: 42387503 ↗
L2COHORTCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Complications, Prognosis and Natural History - [23]
Wabnitz AM. “Management of Large Artery Atherosclerosis.” Continuum (Minneapolis, Minn.) (2026). PMID: 42233827 ↗
L5CASE_REPORTCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications - [24]
Qiao Y, Suri FK, Zhang Y et al.. “Racial Differences in Prevalence and Risk for Intracranial Atherosclerosis in a US Community-Based Population.” JAMA cardiology (2017). PMID: 29094154 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Long-term Guideline-Directed Therapy - [25]
van Rosendael AR, Narula J, Lin FY et al.. “Association of High-Density Calcified 1K Plaque With Risk of Acute Coronary Syndrome.” JAMA cardiology (2020). PMID: 31968065 ↗
L3OTHERCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, History and Evolution of Treatment - [26]
O'Connor KD, Brophy T, Fonarow GC et al.. “Testing for Coronary Artery Disease in Older Patients With New-Onset Heart Failure: Findings From Get With The Guidelines-Heart Failure.” Circulation. Heart failure (2020). PMID: 32207996 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Long-term Guideline-Directed Therapy, History and Evolution of Treatment - [27]
Yeh CF, Ianalieva L, Wong HK et al.. “Nanomedicine-based theranostics in atherosclerotic cardiovascular diseases.” Journal of biomedical science (2026). PMID: 42069590 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation - [28]
Atalla M, Gupta V, Khalid M et al.. “Cardiology: What You May Have Missed in 2025.” Annals of internal medicine (2026). PMID: 41974015 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation - [29]
Lei J, Lu X, Liang Q. “Lipemic anterior chamber mimicking uveitis in severe hypertriglyceridemia: a case report and literature review.” BMC ophthalmology (2026). PMID: 42087131 ↗
L4CASE_REPORTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Complications - [30]
Alzoubi M, Omar Saleh A, Omari FA et al.. “Asymptomatic gallstones: Cumulative incidence proportion, incidence rate, and risk factors for symptoms development: Systematic review and meta-analysis.” PloS one (2026). PMID: 41886405 ↗
L1SR_OBSCited in: Definition, Classification and Nomenclature, Clinical Presentation - [31]
Kayani AMA, Umar MF, Navarro-Martinez D et al.. “Lipid-modifying efficacy and safety of obicetrapib in high-risk cardiovascular patients: A systematic review and meta-analysis.” Vascular diseases (Paris, France) (2026). PMID: 41763910 ↗
L5SR_OBSCited in: Definition, Classification and Nomenclature - [32]
Tang L, He Y, Qiao Z et al.. “Breaking the barrier: oral tacrolimus plus apremilast rescues acute generalized pustular psoriasis with severe comorbidities-a case report.” Frontiers in immunology (2026). PMID: 42344901 ↗
L4CASE_REPORTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment - [33]
Mahmoodi BK, Cushman M, Anne Næss I et al.. “Association of Traditional Cardiovascular Risk Factors With Venous Thromboembolism: An Individual Participant Data Meta-Analysis of Prospective Studies.” Circulation (2016). PMID: 27831499 ↗
L1SR_OBSCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Complications - [34]
Purnell JQ, Zinman B, Brunzell JD. “The effect of excess weight gain with intensive diabetes mellitus treatment on cardiovascular disease risk factors and atherosclerosis in type 1 diabetes mellitus: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) study.” Circulation (2012). PMID: 23212717 ↗
L1RCTCited in: Epidemiology and Risk Factors, Clinical Presentation, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment - [35]
Xie X, Shi X, Zhang Y et al.. “Angiopoietin-Like 3 Antibody Therapy in Patients With Suboptimally Controlled Hyperlipidemia: A Phase 2 Study.” Journal of the American College of Cardiology (2025). PMID: 40167414 ↗
L1RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications - [36]
Haine A, Kavanagh S, Berger JS et al.. “Sex-Specific Risks of Major Cardiovascular and Limb Events in Patients With Symptomatic Peripheral Artery Disease.” Journal of the American College of Cardiology (2020). PMID: 32057375 ↗
L2RCTCited in: Epidemiology and Risk Factors, History and Evolution of Treatment, Prognosis and Natural History - [37]
Boccara F, Kumar PN, Caramelli B et al.. “Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study.” Journal of the American College of Cardiology (2020). PMID: 32234462 ↗
L1RCTCited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications - [38]
Shaw AT, Bauer TM, de Marinis F et al.. “First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.” The New England journal of medicine (2020). PMID: 33207094 ↗
L1RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History - [39]
Ridker PM, Danielson E, Fonseca FA et al.. “Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.” The New England journal of medicine (2008). PMID: 18997196 ↗
L1RCTCited in: Epidemiology and Risk Factors, History and Evolution of Treatment, Prognosis and Natural History - [40]
Basaria S, Coviello AD, Travison TG et al.. “Adverse events associated with testosterone administration.” The New England journal of medicine (2010). PMID: 20592293 ↗
L1RCTCited in: Epidemiology and Risk Factors, Clinical Presentation, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications - [41]
Hudes G, Carducci M, Tomczak P et al.. “Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.” The New England journal of medicine (2007). PMID: 17538086 ↗
L1RCTCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History - [42]
Rossebø AB, Pedersen TR, Boman K et al.. “Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.” The New England journal of medicine (2008). PMID: 18765433 ↗
L1RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History - [43]
Kashani A, Phillips CO, Foody JM et al.. “Risks associated with statin therapy: a systematic overview of randomized clinical trials.” Circulation (2006). PMID: 17159064 ↗
L1REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Long-term Guideline-Directed Therapy, Complications - [44]
Hong KN, Fuster V, Rosenson RS et al.. “How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD.” Journal of the American College of Cardiology (2017). PMID: 29050566 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Complications - [45]
Miller JD, Aronis KN, Chrispin J et al.. “Obesity, Exercise, Obstructive Sleep Apnea, and Modifiable Atherosclerotic Cardiovascular Disease Risk Factors in Atrial Fibrillation.” Journal of the American College of Cardiology (2015). PMID: 26718677 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Long-term Guideline-Directed Therapy, Complications - [46]
Chou R, Dana T, Blazina I et al.. “Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force.” JAMA (2016). PMID: 27838722 ↗
L1SR_OBSCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications, Prognosis and Natural History - [47]
Machline-Carrion MJ, Soares RM, Damiani LP et al.. “Effect of a Multifaceted Quality Improvement Intervention on the Prescription of Evidence-Based Treatment in Patients at High Cardiovascular Risk in Brazil: The BRIDGE Cardiovascular Prevention Cluster Randomized Clinical Trial.” JAMA cardiology (2019). PMID: 30942842 ↗
L1RCTCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment - [48]
Ikramuddin S, Korner J, Lee WJ et al.. “Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial.” JAMA (2013). PMID: 23736733 ↗
L1RCTCited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications - [49]
Kempen JH, Altaweel MM, Holbrook JT et al.. “Association Between Long-Lasting Intravitreous Fluocinolone Acetonide Implant vs Systemic Anti-inflammatory Therapy and Visual Acuity at 7 Years Among Patients With Intermediate, Posterior, or Panuveitis.” JAMA (2017). PMID: 28477440 ↗
L2RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications, Prognosis and Natural History - [50]
Birger M, Kaldjian AS, Roth GA et al.. “Spending on Cardiovascular Disease and Cardiovascular Risk Factors in the United States: 1996 to 2016.” Circulation (2021). PMID: 33926203 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment - [51]
Saha P, Potiny P, Rigdon J et al.. “Substantial Cardiovascular Morbidity in Adults With Lower-Complexity Congenital Heart Disease.” Circulation (2019). PMID: 30813762 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications - [52]
DeCarlo C, Latz CA, Boitano LT et al.. “Prognostication of Asymptomatic Penetrating Aortic Ulcers: A Modern Approach.” Circulation (2021). PMID: 34376058 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, History and Evolution of Treatment, Complications, Prognosis and Natural History - [53]
Caleyachetty R, Thomas GN, Toulis KA et al.. “Metabolically Healthy Obese and Incident Cardiovascular Disease Events Among 3.5 Million Men and Women.” Journal of the American College of Cardiology (2017). PMID: 28911506 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Complications - [54]
Lee HH, Crawford EB, Cho SMJ et al.. “Trends in Prevalence, Treatment, and Control of Cardiometabolic Risk Factors Among Adults With Hypertension in the United States, 1999-2023.” Journal of the American College of Cardiology (2025). PMID: 41295934 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy - [55]
Sinha A, Ning H, Carnethon MR et al.. “Race- and Sex-Specific Population Attributable Fractions of Incident Heart Failure: A Population-Based Cohort Study From the Lifetime Risk Pooling Project.” Circulation. Heart failure (2021). PMID: 33761754 ↗
L2COHORTCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification - [56]
Markus MRP, Ittermann T, Mariño Coronado J et al.. “Low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events.” European heart journal (2025). PMID: 40320753 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup, Complications - [57]
Wu J, Zafar MA, Liu Y et al.. “Fate of the unoperated ascending thoracic aortic aneurysm: three-decade experience from the Aortic Institute at Yale University.” European heart journal (2023). PMID: 36994934 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Acute and Initial Management, History and Evolution of Treatment, Complications, Prognosis and Natural History - [58]
Rafiee M, Mehmandoost S, Harandi F et al.. “Prevalence of Hypertension, Diabetes, Obesity, and High Cholesterol Among Older People Living With HIV: A Systematic Review and Meta-Analysis.” AIDS research and treatment (2026). PMID: 42358331 ↗
L1SR_OBSCited in: Epidemiology and Risk Factors - [59]
Magnussen C, Alegre-Diaz J, Al-Nasser LA et al.. “Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.” The New England journal of medicine (2025). PMID: 40162648 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Clinical Presentation, Acute and Initial Management, Complications, Prognosis and Natural History - [60]
Wang N, Li M, Lu M et al.. “Therapeutic effects and mechanisms of Artemisia species on metabolic diseases: A systematic review.” Medicine (2026). PMID: 42332507 ↗
L5SR_OBSCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy - [61]
Sadeghi E, Kozlov M, Hasan N et al.. “Associations between psychiatric disorders and medication use, and retinal occlusion: a large-scale retrospective cohort study.” Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2026). PMID: 42371026 ↗
L3COHORTCited in: Epidemiology and Risk Factors, Prognosis and Natural History - [62]
Thangjui S, Knutsen K, Hollowell B et al.. “Natural history and outcomes of post-operative atrial fibrillation after non-cardiac surgery: a clinically adjudicated single-center retrospective study.” Clinical research in cardiology : official journal of the German Cardiac Society (2026). PMID: 42370998 ↗
L3COHORTCited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Prognosis and Natural History - [63]
Ul-Haq I, Alqahtani HS, Shaheen NA et al.. “Incidence and Risk Factors of Diabetic Retinopathy in Patients with Type 1 Diabetes Mellitus: A Retrospective Study in NGHA, Riyadh, Saudi Arabia.” Journal of clinical medicine (2026). PMID: 42194771 ↗
L3COHORTCited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy - [64]
Liu M, Marinacci LX, Joynt Maddox KE et al.. “Cardiovascular Health Among Rural and Urban US Adults-Healthcare, Lifestyle, and Social Factors.” JAMA cardiology (2025). PMID: 40163358 ↗
L2OTHERCited in: Epidemiology and Risk Factors - [65]
Oseran AS, Sun T, Wadhera RK. “Health Care Access and Management of Cardiovascular Risk Factors Among Working-Age Adults With Low Income by State Medicaid Expansion Status.” JAMA cardiology (2022). PMID: 35648424 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy - [66]
Tung EL, Wroblewski KE, Makelarski JA et al.. “Childhood Parental Incarceration and Adult-Onset Hypertension and Cardiovascular Risk.” JAMA cardiology (2023). PMID: 37647038 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Complications, Prognosis and Natural History - [67]
Gong J, Vaduganathan M, Wadhera RK. “Chronic Kidney Disease Prevalence and Awareness Among US Adults.” JAMA cardiology (2026). PMID: 41205219 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy, Special Populations and Prevention - [68]
Brandt EJ, Chang T, Leung C et al.. “Food Insecurity Among Individuals With Cardiovascular Disease and Cardiometabolic Risk Factors Across Race and Ethnicity in 1999-2018.” JAMA cardiology (2022). PMID: 36170056 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Complications - [69]
Whelton SP, McEvoy JW, Shaw L et al.. “Association of Normal Systolic Blood Pressure Level With Cardiovascular Disease in the Absence of Risk Factors.” JAMA cardiology (2020). PMID: 32936272 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Severity Staging and Risk Stratification - [70]
Bansal N, Katz R, Robinson-Cohen C et al.. “Absolute Rates of Heart Failure, Coronary Heart Disease, and Stroke in Chronic Kidney Disease: An Analysis of 3 Community-Based Cohort Studies.” JAMA cardiology (2017). PMID: 28002548 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Complications, Special Populations and Prevention - [71]
Honigberg MC, Zekavat SM, Aragam K et al.. “Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease.” JAMA (2019). PMID: 31738818 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Prognosis and Natural History - [72]
Aggarwal R, Yeh RW, Joynt Maddox KE et al.. “Cardiovascular Risk Factor Prevalence, Treatment, and Control in US Adults Aged 20 to 44 Years, 2009 to March 2020.” JAMA (2023). PMID: 36871237 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Acute and Initial Management, History and Evolution of Treatment - [73]
Record NB, Onion DK, Prior RE et al.. “Community-wide cardiovascular disease prevention programs and health outcomes in a rural county, 1970-2010.” JAMA (2015). PMID: 25585326 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Special Populations and Prevention - [74]
Gelfand JM, Neimann AL, Shin DB et al.. “Risk of myocardial infarction in patients with psoriasis.” JAMA (2006). PMID: 17032986 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Prognosis and Natural History - [75]
McTigue K, Larson JC, Valoski A et al.. “Mortality and cardiac and vascular outcomes in extremely obese women.” JAMA (2006). PMID: 16820550 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Complications, Prognosis and Natural History - [76]
Qin H, Tromp J, Ter Maaten JM et al.. “Clinical and Proteomic Risk Profiles of New-Onset Heart Failure in Men and Women.” JACC. Heart failure (2024). PMID: 39708029 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup, Severity Staging and Risk Stratification, History and Evolution of Treatment, Complications - [77]
Xu Y, Yang H, Xu Q et al.. “Distinct From the Adult Paradigm: Re-Evaluate the Pathophysiological and Therapeutic Framework in Children and Adolescent Hyperlipidaemia.” Current obesity reports (2026). PMID: 42287583 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism - [78]
Wang S, Wang L, Shi D et al.. “Relationship between hyperlipidemia and lumbar disc degeneration in patients with low back pain: an observational retrospective study.” Frontiers in physiology (2026). PMID: 42318506 ↗
L3COHORTCited in: Epidemiology and Risk Factors, Prognosis and Natural History - [79]
Yang W, Hu W, Pan Y et al.. “Impact of preoperative dual antiplatelet therapy vs. aspirin monotherapy on perioperative outcomes in carotid endarterectomy patients: a retrospective cohort study.” International journal of clinical pharmacy (2026). PMID: 42171869 ↗
L2COHORTCited in: Epidemiology and Risk Factors, Complications - [80]
Piña IL, Zheng Q, She L et al.. “Sex Difference in Patients With Ischemic Heart Failure Undergoing Surgical Revascularization: Results From the STICH Trial (Surgical Treatment for Ischemic Heart Failure).” Circulation (2018). PMID: 29459462 ↗
L1RCTCited in: Pathophysiology and Mechanism, Acute and Initial Management, Prognosis and Natural History - [81]
Ghattas A, Griffiths HR, Devitt A et al.. “Monocytes in coronary artery disease and atherosclerosis: where are we now?” Journal of the American College of Cardiology (2013). PMID: 23973684 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, Prognosis and Natural History - [82]
Bravata DM, Smith-Spangler C, Sundaram V et al.. “Using pedometers to increase physical activity and improve health: a systematic review.” JAMA (2007). PMID: 18029834 ↗
L2SR_OBSCited in: Pathophysiology and Mechanism, Clinical Presentation - [83]
Lee JK, Grace KA, Taylor AJ. “Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial.” JAMA (2006). PMID: 17101639 ↗
L1RCTCited in: Pathophysiology and Mechanism, Clinical Presentation, History and Evolution of Treatment, Prognosis and Natural History, Special Populations and Prevention - [84]
Gu H, Wen J, Liu Y et al.. “SREBP1 Transactivation of NHE3 Impairs Cardiac Contraction and Aggravates Heart Failure.” Circulation (2026). PMID: 42170742 ↗
L5OTHERCited in: Pathophysiology and Mechanism - [85]
Drechsler M, Megens RT, van Zandvoort M et al.. “Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis.” Circulation (2010). PMID: 20956207 ↗
L5OTHERCited in: Pathophysiology and Mechanism, Complications - [86]
Li X, Zhu M, Penfold ME et al.. “Activation of CXCR7 limits atherosclerosis and improves hyperlipidemia by increasing cholesterol uptake in adipose tissue.” Circulation (2013). PMID: 24374972 ↗
L5OTHERCited in: Pathophysiology and Mechanism - [87]
Koskinas KC, Feldman CL, Chatzizisis YS et al.. “Natural history of experimental coronary atherosclerosis and vascular remodeling in relation to endothelial shear stress: a serial, in vivo intravascular ultrasound study.” Circulation (2010). PMID: 20439786 ↗
L5OTHERCited in: Pathophysiology and Mechanism, Diagnosis and Workup, History and Evolution of Treatment, Prognosis and Natural History - [88]
Lerman JB, Joshi AA, Chaturvedi A et al.. “Coronary Plaque Characterization in Psoriasis Reveals High-Risk Features That Improve After Treatment in a Prospective Observational Study.” Circulation (2017). PMID: 28483812 ↗
L2OTHERCited in: Pathophysiology and Mechanism, Diagnosis and Workup - [89]
Seehaus S, Shahzad K, Kashif M et al.. “Hypercoagulability inhibits monocyte transendothelial migration through protease-activated receptor-1-, phospholipase-Cbeta-, phosphoinositide 3-kinase-, and nitric oxide-dependent signaling in monocytes and promotes plaque stability.” Circulation (2009). PMID: 19687358 ↗
L5OTHERCited in: Pathophysiology and Mechanism - [90]
Xiao H, Lu M, Lin TY et al.. “Sterol regulatory element binding protein 2 activation of NLRP3 inflammasome in endothelium mediates hemodynamic-induced atherosclerosis susceptibility.” Circulation (2013). PMID: 23838163 ↗
L5OTHERCited in: Pathophysiology and Mechanism - [91]
Alvi RM, Neilan AM, Tariq N et al.. “Protease Inhibitors and Cardiovascular Outcomes in Patients With HIV and Heart Failure.” Journal of the American College of Cardiology (2018). PMID: 30049313 ↗
L2OTHERCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Long-term Guideline-Directed Therapy, Prognosis and Natural History - [92]
Jaguan D, Gratz BW, Jaguan SI et al.. “Treatment of Generalized Granuloma Annulare with JAK Inhibitors: Systematic Review.” Clinical, cosmetic and investigational dermatology (2026). PMID: 42111237 ↗
L2SR_OBSCited in: Pathophysiology and Mechanism, Complications - [93]
Oshitari T. “Pathogenesis of Non-Arteritic Anterior Ischemic Optic Neuropathy Associated with COVID-19.” International journal of molecular sciences (2026). PMID: 41898506 ↗
L5CASE_REPORTCited in: Pathophysiology and Mechanism - [94]
King WC, Hinerman AS, Belle SH et al.. “Comparison of the Performance of Common Measures of Weight Regain After Bariatric Surgery for Association With Clinical Outcomes.” JAMA (2018). PMID: 30326125 ↗
L2OTHERCited in: Pathophysiology and Mechanism, Clinical Presentation, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications - [95]
Wijeysundera HC, Machado M, Farahati F et al.. “Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005.” JAMA (2010). PMID: 20460623 ↗
L2OTHERCited in: Pathophysiology and Mechanism, Clinical Presentation, Acute and Initial Management - [96]
Hall JE, Omoto ACM, do Carmo JM et al.. “Cardiometabolic regulation by adipocyte-derived leptin and the brain melanocortin system.” Clinical science (London, England : 1979) (2026). PMID: 42340064 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Complications - [97]
Foroohar T, Berk-Krauss J, Caplan AS et al.. “Granuloma Annulare: An Updated Review of Epidemiology, Molecular Pathogenesis, and Management.” Journal of the American Academy of Dermatology (2026). PMID: 42320859 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Long-term Guideline-Directed Therapy - [98]
Subauste CS. “Advances in the Role of the CD40-CD154 Pathway in the Pathogenesis of Diabetic Retinopathy.” International journal of molecular sciences (2026). PMID: 42123447 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism - [99]
Jovanovic K, Jovandaric MZ, Jovanovic D et al.. “Altered Lipid Profile and Oxidative Stress During Pregnancy: Impact on the Fetus and Risk of Metabolic Disorders in Adulthood.” International journal of molecular sciences (2026). PMID: 42123329 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Special Populations and Prevention - [100]
Lin L, Zi S, Zhang G et al.. “Advances in the pathogenesis of MASLD and its association with neutrophils.” Frontiers in medicine (2026). PMID: 41889493 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism - [101]
Kaplan R, Berni M, Caliogna L et al.. “Pathogenesis of Shoulder Calcific Tendinopathy.” International journal of molecular sciences (2026). PMID: 41828406 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism - [102]
Zhang M, Liu WL, Xu G et al.. “Hyperlipidemia in membranous nephropathy.” Clinical kidney journal (2026). PMID: 41822057 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism - [103]
Hsu JJ, Li Q, Tintut Y et al.. “Considerations in the Use of Mouse Models of Vascular and Valvular Calcification.” Arteriosclerosis, thrombosis, and vascular biology (2026). PMID: 41739911 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism - [104]
Navar-Boggan AM, Peterson ED, D'Agostino RB et al.. “Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease.” Circulation (2015). PMID: 25623155 ↗
L2OTHERCited in: Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy - [105]
Pande RL, Perlstein TS, Beckman JA et al.. “Association of insulin resistance and inflammation with peripheral arterial disease: the National Health and Nutrition Examination Survey, 1999 to 2004.” Circulation (2008). PMID: 18559705 ↗
L4OTHERCited in: Clinical Presentation - [106]
Fracassi F, Crea F, Sugiyama T et al.. “Healed Culprit Plaques in Patients With Acute Coronary Syndromes.” Journal of the American College of Cardiology (2019). PMID: 31072568 ↗
L2OTHERCited in: Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History - [107]
Kanner AM, Bicchi MM. “Antiseizure Medications for Adults With Epilepsy: A Review.” JAMA (2022). PMID: 35380580 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications - [108]
Choi SI, Heo Y, Ryu SW et al.. “Safety, Efficacy, and Quality of Life Outcomes of Bariatric and Metabolic Surgery in Korea: A Prospective Multicenter Cohort Study.” Obesity surgery (2026). PMID: 42098468 ↗
L2COHORTCited in: Clinical Presentation - [109]
Lu Z, Zong D, Yang Z et al.. “Risk factors for rebleeding in acute lower gastrointestinal bleeding: a systematic review and meta-analysis.” International journal of colorectal disease (2026). PMID: 42287444 ↗
L1SR_OBSCited in: Clinical Presentation, Acute and Initial Management - [110]
Tu Y, Sun Y, Zhu M et al.. “Bilateral extensive adult-onset limbal xanthogranuloma invading the deep corneal stroma: a case report and literature review.” Frontiers in medicine (2026). PMID: 42369137 ↗
L4CASE_REPORTCited in: Clinical Presentation, History and Evolution of Treatment - [111]
Laffin LJ, Bruemmer D, Garcia M et al.. “Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers.” Journal of the American College of Cardiology (2022). PMID: 36351465 ↗
L1RCTCited in: Diagnosis and Workup, History and Evolution of Treatment, Complications - [112]
Miller JD, Weiss RM, Serrano KM et al.. “Lowering plasma cholesterol levels halts progression of aortic valve disease in mice.” Circulation (2009). PMID: 19433756 ↗
L5OTHERCited in: Diagnosis and Workup, Complications - [113]
Roifman I, Therrien J, Ionescu-Ittu R et al.. “Coarctation of the aorta and coronary artery disease: fact or fiction?” Circulation (2012). PMID: 22675158 ↗
L2OTHERCited in: Diagnosis and Workup - [114]
Masri A, Kalahasti V, Svensson LG et al.. “Aortic Cross-Sectional Area/Height Ratio and Outcomes in Patients With a Trileaflet Aortic Valve and a Dilated Aorta.” Circulation (2016). PMID: 27770001 ↗
L2OTHERCited in: Diagnosis and Workup, Prognosis and Natural History - [115]
Miller TD, Redberg RF, Wackers FJ. “Screening asymptomatic diabetic patients for coronary artery disease: why not?” Journal of the American College of Cardiology (2006). PMID: 16904546 ↗
L5OTHERCited in: Diagnosis and Workup, Severity Staging and Risk Stratification, Prognosis and Natural History - [116]
Cavusoglu E, Kornecki E, Sobocka MB et al.. “Association of plasma levels of F11 receptor/junctional adhesion molecule-A (F11R/JAM-A) with human atherosclerosis.” Journal of the American College of Cardiology (2007). PMID: 17964041 ↗
L4OTHERCited in: Diagnosis and Workup, Severity Staging and Risk Stratification - [117]
Civeira F, Jarauta E, Cenarro A et al.. “Frequency of low-density lipoprotein receptor gene mutations in patients with a clinical diagnosis of familial combined hyperlipidemia in a clinical setting.” Journal of the American College of Cardiology (2008). PMID: 19007590 ↗
L4OTHERCited in: Diagnosis and Workup, Severity Staging and Risk Stratification - [118]
Zeng Y, Sun Y. “Predictive value of serial dynamic lipid monitoring for pathologic complete response to neoadjuvant chemotherapy in luminal breast cancer: a retrospective study integrating metabolic and clinical indicators.” BMC women's health (2026). PMID: 41952141 ↗
L2COHORTCited in: Diagnosis and Workup, Severity Staging and Risk Stratification - [119]
Chiang LH, Tsai PH, Chen YF et al.. “Real-World Safety and Retention of Tofacitinib in Elderly Versus Non-elderly Patients With Rheumatoid Arthritis: A Retrospective Cohort Study in Taiwan.” International journal of rheumatic diseases (2026). PMID: 42177625 ↗
L2COHORTCited in: Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy - [120]
Zhou X, Yang C, Zou T et al.. “Shared Genetic Risk Between Acute Pancreatitis and Metabolic Syndrome Converges on a BCAT1-Positive Fibroblast Subpopulation and MAPK14-Driven Inflammation.” FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2026). PMID: 42402174 ↗
L2OTHERCited in: Diagnosis and Workup, Acute and Initial Management - [121]
Qin Y, Hong Y, Ning L et al.. “Subtype-Specific Associations Between Hyperlipidemia and Age-Related Cataract: A Clinic-Based Cross-Sectional Study.” Clinical interventions in aging (2026). PMID: 42333214 ↗
L4OTHERCited in: Diagnosis and Workup - [122]
Li S, Wen ZQ, Yan P. “Zexie decoction alleviates hyperlipidemia through modulation of the PPAR signaling pathway and lysophospholipid metabolism.” Pharmaceutical biology (2026). PMID: 42295113 ↗
L5OTHERCited in: Diagnosis and Workup - [123]
Huang X, Lu N, Yu H et al.. “The impact of 1-hour plasma glucose on the metabolic characteristics and pregnancy outcomes in polycystic ovary syndrome.” Nutrition & diabetes (2026). PMID: 42285965 ↗
L2OTHERCited in: Diagnosis and Workup - [124]
Yin WL, Peng L, Zhang JH et al.. “Hyperlipid-Related Alzheimer's Disease: Potential Role of CircUCK2/miR-24-3p/p38 Axis in Neuronal Damage.” Comprehensive Physiology (2026). PMID: 42281258 ↗
L3OTHERCited in: Diagnosis and Workup - [125]
Nagaoka M, Nagaoka K, Kajitani N et al.. “Serum Mac-2 Binding Protein Glycan Isomer and Cerebral White Matter Injury in Older Adults: A Hepatic-Cerebral Link.” Hepatology research : the official journal of the Japan Society of Hepatology (2026). PMID: 42246447 ↗
L4OTHERCited in: Diagnosis and Workup - [126]
Zhong XY, Peng R, Deng Y et al.. “Drinking Patterns and CT/MRI Feature-Based Nomogram Models Can More Accurately Predict Acute Alcoholic Pancreatitis Recurrence.” Alcohol, clinical & experimental research (2026). PMID: 42246257 ↗
L3OTHERCited in: Diagnosis and Workup - [127]
Li W, Fredriksson M, Dernroth DN et al.. “Sex differences in iron stores and associations of body iron with cardiovascular risk factors in the middle-aged general population.” Frontiers in endocrinology (2026). PMID: 42222086 ↗
L4OTHERCited in: Diagnosis and Workup - [128]
Ata HS, Abd El-Rady NM, Gomaa AMS et al.. “Neurodegenerative and Glial Physiology in Diabetic Retinopathy: Dissociated Effects of Forskolin on Neuronal Survival and Glial Activation.” Biomedicines (2026). PMID: 42193428 ↗
L5OTHERCited in: Diagnosis and Workup - [129]
Ridker PM, MacFadyen J, Cressman M et al.. “Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial.” Journal of the American College of Cardiology (2010). PMID: 20206456 ↗
L1TRIAL_NONRANDOMCited in: Severity Staging and Risk Stratification, Special Populations and Prevention - [130]
Zhang D, Jiang X, Fang P et al.. “Hyperhomocysteinemia promotes inflammatory monocyte generation and accelerates atherosclerosis in transgenic cystathionine beta-synthase-deficient mice.” Circulation (2009). PMID: 19858416 ↗
L5OTHERCited in: Severity Staging and Risk Stratification - [131]
Fu J, Zhou Y, Zhang F et al.. “Risk factors for postoperative venous thromboembolism in patients with lung cancer: a systematic review and meta-analysis.” Frontiers in medicine (2026). PMID: 41613334 ↗
L2SR_OBSCited in: Severity Staging and Risk Stratification - [132]
Wu HL, Chen JT, Cata JP et al.. “Preoperative proprotein convertase subtilisin/kexin type 9 inhibitors versus statins and postoperative adverse events in hyperlipidemia: A nationwide, active-comparator cohort study.” Atherosclerosis (2026). PMID: 42048760 ↗
L2COHORTCited in: Severity Staging and Risk Stratification, Prognosis and Natural History - [133]
Wolff K, Gumin D, Shqara RA et al.. “Risk factors and predictive modeling for occult endometrial cancer in women with atypical hyperplasia: a retrospective study.” Archives of gynecology and obstetrics (2026). PMID: 41611996 ↗
L3COHORTCited in: Severity Staging and Risk Stratification - [134]
Zhong W, Jiang F, Wang H et al.. “Polypharmacy, determinants, and adverse outcomes in elderly patients with heart failure: a multicenter retrospective cohort study of 7,361 subjects.” BMC geriatrics (2026). PMID: 41588351 ↗
L2COHORTCited in: Severity Staging and Risk Stratification, Special Populations and Prevention - [135]
Li J, Wang Y, Chen Z et al.. “Association between autologous blood transfusion and serum creatinine in patients with acute Stanford-A aortic dissection based on a retrospective study.” BMC anesthesiology (2026). PMID: 41566236 ↗
L3COHORTCited in: Severity Staging and Risk Stratification - [136]
Zhang Y, Zhang X, Song H et al.. “Predicting short-term composite outcome risk in heart failure patients using a machine learning model incorporating UHR: a retrospective cohort study.” Frontiers in nutrition (2026). PMID: 42305866 ↗
L2COHORTCited in: Severity Staging and Risk Stratification, History and Evolution of Treatment - [137]
Shen Q, Zhou S, Ouyang X et al.. “Comorbidity burden and survival in patients with idiopathic pulmonary fibrosis: a real-world cohort study.” Heart & lung : the journal of critical care (2026). PMID: 42030746 ↗
L2COHORTCited in: Severity Staging and Risk Stratification - [138]
Cheng ZT, Wang JL, Zhao YB et al.. “Association Between the Lactate-to-Albumin Ratio and ICU/In-Hospital Mortality in Critically Ill Patients With Comorbid Type 2 Diabetes Mellitus : A Cohort Study Utilizing the MIMIC-IV Database.” Emergency medicine international (2026). PMID: 41982276 ↗
L2COHORTCited in: Severity Staging and Risk Stratification - [139]
Vega RB, O'Mahony G, Barbour AM et al.. “Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients.” Circulation (2026). PMID: 42137960 ↗
L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment - [140]
Ballantyne CM, Gaudet D, Rosenson RS et al.. “Effect of Targeting ApoC-III With Plozasiran on Lipoprotein Particle Size and Number in Hypertriglyceridemia.” Journal of the American College of Cardiology (2025). PMID: 40099777 ↗
L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment - [141]
McKenney JM, Farnier M, Lo KW et al.. “Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia.” Journal of the American College of Cardiology (2006). PMID: 16630994 ↗
L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment - [142]
Rosenson RS, Gaudet D, Hegele RA et al.. “Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia.” The New England journal of medicine (2024). PMID: 38809174 ↗
L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment - [143]
Blom DJ, Hala T, Bolognese M et al.. “A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.” The New England journal of medicine (2014). PMID: 24678979 ↗
L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications - [144]
Ballantyne CM, Vasas S, Azizad M et al.. “Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia.” The New England journal of medicine (2024). PMID: 38804517 ↗
L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment - [145]
Ridker PM, Tardif JC, Amarenco P et al.. “Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab.” The New England journal of medicine (2017). PMID: 28304227 ↗
L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications - [146]
Puzziferri N, Roshek TB, Mayo HG et al.. “Long-term follow-up after bariatric surgery: a systematic review.” JAMA (2014). PMID: 25182102 ↗
L2SR_OBSCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications, Prognosis and Natural History - [147]
Berthold HK, Unverdorben S, Degenhardt R et al.. “Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial.” JAMA (2006). PMID: 16705107 ↗
L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History - [148]
Smilowitz NR, Mega JL, Berger JS. “Duration of anticoagulation for venous thromboembolic events.” Circulation (2014). PMID: 25539522 ↗
L4CASE_REPORTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment - [149]
Schwab RD, Degaramo D, Hong SJ et al.. “Chimeric Antigen Receptor Regulatory T Cells Targeted Against Oxidized Low-Density Lipoprotein Reduce Atherosclerotic Plaque Development.” Circulation (2025). PMID: 41268661 ↗
L5OTHERCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy - [150]
Al Mheid I, Quyyumi AA. “Vitamin D and Cardiovascular Disease: Controversy Unresolved.” Journal of the American College of Cardiology (2017). PMID: 28662812 ↗
L5REVIEW_NARRATIVECited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications - [151]
Moccetti F, Brown E, Xie A et al.. “Myocardial Infarction Produces Sustained Proinflammatory Endothelial Activation in Remote Arteries.” Journal of the American College of Cardiology (2018). PMID: 30139430 ↗
L5OTHERCited in: Acute and Initial Management - [152]
Hsu J, Price M, Huang J et al.. “Unintended consequences of caps on Medicare drug benefits.” The New England journal of medicine (2006). PMID: 16738271 ↗
L2OTHERCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy - [153]
Jackevicius CA, Tu JV, Ross JS et al.. “Use of ezetimibe in the United States and Canada.” The New England journal of medicine (2008). PMID: 18375999 ↗
L2OTHERCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy - [154]
Meng X, Ou Y, Mao J et al.. “LDAR outperforms other albumin-derived indices in predicting 28-day ICU mortality in critically ill myocardial infarction patients: a two-cohort study.” Frontiers in medicine (2026). PMID: 42221102 ↗
L2COHORTCited in: Acute and Initial Management - [155]
Whitmer RA, Karter AJ, Yaffe K et al.. “Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus.” JAMA (2009). PMID: 19366776 ↗
L2OTHERCited in: Acute and Initial Management - [156]
Choi H, Choi J, Maksatbekov C et al.. “Predictors of in-hospital case-fatality in patients with stroke at the National Hospital of the Kyrgyz Republic: a retrospective cohort study.” BMC neurology (2026). PMID: 42216139 ↗
L2COHORTCited in: Acute and Initial Management - [157]
Devanita S LA, Adhyatma IGR, Cahya KKD. “Risk factors of cerebral vasospasm associated with ruptured arterio-venous malformation: A systematic review and meta-analysis.” Journal of cerebrovascular and endovascular neurosurgery (2026). PMID: 42374993 ↗
L2SR_OBSCited in: Acute and Initial Management - [158]
Liao HW, Luyckx V, Ostermann M et al.. “Severe Pregnancy-Associated Acute Kidney Injury and Maternal Vulnerability.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2026). PMID: 42406539 ↗
L2OTHERCited in: Acute and Initial Management - [159]
Jiang Q, Wang R, He Y et al.. “Construction and Validation of a 90-Day Mortality Risk Prediction Model Based on Interpretable Machine Learning for Acute Ischemic Stroke Patients Undergoing Mechanical Thrombectomy.” Journal of clinical medicine (2026). PMID: 42355869 ↗
L2OTHERCited in: Acute and Initial Management - [160]
Foody JM, Shah R, Galusha D et al.. “Statins and mortality among elderly patients hospitalized with heart failure.” Circulation (2006). PMID: 16490817 ↗
L2OTHERCited in: Long-term Guideline-Directed Therapy, Prognosis and Natural History, Special Populations and Prevention - [161]
Bair TL, Muhlestein JB, May HT et al.. “Surgical revascularization is associated with improved long-term outcomes compared with percutaneous stenting in most subgroups of patients with multivessel coronary artery disease: results from the Intermountain Heart Registry.” Circulation (2007). PMID: 17846308 ↗
L2OTHERCited in: Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Prognosis and Natural History - [162]
Piazza G, Campia U, Hurwitz S et al.. “Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19.” Journal of the American College of Cardiology (2020). PMID: 33121712 ↗
L2OTHERCited in: Long-term Guideline-Directed Therapy, Prognosis and Natural History - [163]
Allard NAE, Janssen L, Aussieker T et al.. “Moderate Intensity Exercise Training Improves Skeletal Muscle Performance in Symptomatic and Asymptomatic Statin Users.” Journal of the American College of Cardiology (2021). PMID: 34794683 ↗
L2OTHERCited in: Long-term Guideline-Directed Therapy - [164]
Mancini GBJ, Lincoff AM, Goldberg AC et al.. “Efficacy and Safety of Bempedoic Acid in Patients Aged ≥75 Years Stratified by Varying Statin Exposure: Results From Phase 3 Studies of Bempedoic Acid.” Journal of the American Heart Association (2026). PMID: 42333640 ↗
L1RCTCited in: Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Special Populations and Prevention - [165]
Reges O, Greenland P, Dicker D et al.. “Association of Bariatric Surgery Using Laparoscopic Banding, Roux-en-Y Gastric Bypass, or Laparoscopic Sleeve Gastrectomy vs Usual Care Obesity Management With All-Cause Mortality.” JAMA (2018). PMID: 29340677 ↗
L2OTHERCited in: Long-term Guideline-Directed Therapy - [166]
Wu J, Zhang F, Li Q et al.. “Predictors of difficult vascular access during transradial neurointervention: a retrospective study.” Revista da Associacao Medica Brasileira (1992) (2026). PMID: 42339907 ↗
L2COHORTCited in: Long-term Guideline-Directed Therapy - [167]
Duan Y, Pan Z, Gu J et al.. “Disparities in anticoagulation therapy for older adults with non-valvular atrial fibrillation: a comparative study of urban and suburban communities.” BMC geriatrics (2026). PMID: 42420880 ↗
L4OTHERCited in: Long-term Guideline-Directed Therapy - [168]
Papatheodoridis G, Buti M, Yilmaz Y et al.. “Chronic Viral Hepatitis With MASLD: Implications for Clinical and Patient-Reported Outcomes.” Journal of gastroenterology and hepatology (2026). PMID: 42419754 ↗
L4OTHERCited in: Long-term Guideline-Directed Therapy - [169]
Yu M, Lei C, Zou T et al.. “Multidimensional factors influencing the recovery trajectory of residual dizziness after successful canalith repositioning in benign paroxysmal positional vertigo: an ordered logistic regression analysis.” European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery (2026). PMID: 42402503 ↗
L2OTHERCited in: Long-term Guideline-Directed Therapy - [170]
Jafari EA. “Hypertension among Middle Eastern and North African adults residing in the United States: addressing equity in health research representation using the All of Us Research Program, 2000-2024.” Frontiers in medicine (2026). PMID: 42383063 ↗
L2OTHERCited in: Long-term Guideline-Directed Therapy - [171]
Dabour MS, Shaaban A, Duprez DA et al.. “Is endothelial dysfunction induced by aromatase inhibitors reversible after treatment?” Breast cancer research and treatment (2026). PMID: 42329476 ↗
L2OTHERCited in: Long-term Guideline-Directed Therapy - [172]
Peng L, Zhu N, Zhang CJ et al.. “Beyond lipid-lowering effects: Challenges and insights in fenofibrate repurposing for oncology.” Life sciences (2026). PMID: 42302925 ↗
L5REVIEW_NARRATIVECited in: Long-term Guideline-Directed Therapy - [173]
Han X, Hopkins SC, Zhang Z et al.. “The Economic Impact of Cumulative Metabolic Comorbidity Burden in Schizophrenia: A Claims-Based Analysis of Medical Costs in the United States.” Neurology and therapy (2026). PMID: 42301550 ↗
L2OTHERCited in: Long-term Guideline-Directed Therapy - [174]
Zhang X, Xu H, Yu J et al.. “Immune Regulation of the Liver Through the PCSK9/CD36 Pathway During Heart Transplant Rejection.” Circulation (2023). PMID: 37232170 ↗
L5OTHERCited in: Interventional and Device Therapy, Prognosis and Natural History - [175]
Kim YH, Park DW, Lee SW et al.. “Long-term safety and effectiveness of unprotected left main coronary stenting with drug-eluting stents compared with bare-metal stents.” Circulation (2009). PMID: 19620506 ↗
L2OTHERCited in: Interventional and Device Therapy, Special Populations and Prevention - [176]
Koupenova M, Johnston-Cox H, Vezeridis A et al.. “A2b adenosine receptor regulates hyperlipidemia and atherosclerosis.” Circulation (2011). PMID: 22144568 ↗
L5OTHERCited in: Interventional and Device Therapy - [177]
Thomas M, Schymik G, Walther T et al.. “One-year outcomes of cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) registry: the European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve.” Circulation (2011). PMID: 21747054 ↗
L4OTHERCited in: Interventional and Device Therapy, Prognosis and Natural History - [178]
Yu E, Calvert PA, Mercer JR et al.. “Mitochondrial DNA damage can promote atherosclerosis independently of reactive oxygen species through effects on smooth muscle cells and monocytes and correlates with higher-risk plaques in humans.” Circulation (2013). PMID: 23841983 ↗
L4OTHERCited in: Interventional and Device Therapy - [179]
Molony DS, Hung O, Corban M et al.. “A randomized prospective study investigating the relationship between post-PCI wall shear stress and 12-month neointimal healing: The SHEAR-STENT study.” Cardiovascular revascularization medicine : including molecular interventions (2025). PMID: 41285658 ↗
L1RCTCited in: Interventional and Device Therapy - [180]
Önder R, Geebelen G, Scherrenberg M et al.. “The impact of cardiac rehabilitation on atrial fibrillation recurrence after pulmonary vein isolation: results of a large retrospective study.” Frontiers in cardiovascular medicine (2026). PMID: 41674867 ↗
L2COHORTCited in: Interventional and Device Therapy - [181]
Zhu Q, Zhang Y, Liu J et al.. “Clinical validation study of a novel prognostic risk prediction model (CHIP Score) for interventional therapy in patients with NSTE-ACS-a single-center retrospective cohort study based on 348 patients.” BMC cardiovascular disorders (2026). PMID: 41507846 ↗
L2COHORTCited in: Interventional and Device Therapy - [182]
Li W, Zhang G, Chen Y et al.. “Incidence and risk factors of posttransplant diabetes mellitus in lung transplant recipients: a retrospective cohort study.” Journal of thoracic disease (2025). PMID: 41376958 ↗
L2COHORTCited in: Interventional and Device Therapy - [183]
Lin X, Wang Y, Tan S et al.. “Long-term safety, effectiveness, and cost of rapamycin- vs. everolimus-eluting stents in acute coronary syndrome: a real-world cohort study.” International journal of clinical pharmacy (2025). PMID: 41369785 ↗
L2COHORTCited in: Interventional and Device Therapy - [184]
Yen WC, Yang MH, Weng TH et al.. “Dialysis and the risk of early urological cancer: A nationwide population-based cohort study in Taiwan.” Medicine (2025). PMID: 40388720 ↗
L2COHORTCited in: Interventional and Device Therapy - [185]
Wu P, Kiram A, Zhu Y et al.. “Muscle-derived ANXA2 promotes hepatic steatosis by activating SREBP1c-mediated de novo lipogenesis.” Metabolism: clinical and experimental (2026). PMID: 42225205 ↗
L5OTHERCited in: Interventional and Device Therapy - [186]
Wang X, Song Y, Zhao W et al.. “Cinnamaldehyde mitigates MASLD through SIRT1/FOXO1-induced autophagy and synergistic gut microbiota modulation.” NPJ science of food (2026). PMID: 41957048 ↗
L5OTHERCited in: Interventional and Device Therapy - [187]
Williams ZE, Singh I, Marks N et al.. “Innovative wound management of refractory venous ulcers with topical oxygen therapy.” Journal of vascular surgery. Venous and lymphatic disorders (2026). PMID: 41864536 ↗
L4OTHERCited in: Interventional and Device Therapy - [188]
Zhang Y, Teng M, He W et al.. “4-Hydroxybenzyl Alcohol Mitigates Hyperlipidemia-Associated Depression by Inhibiting Neuroinflammation via the NKIRAS2/NF-κB Pathway.” Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2026). PMID: 41801218 ↗
L5OTHERCited in: Interventional and Device Therapy - [189]
Torosian K, Díaz LA, Tesfai K et al.. “Cardiometabolic Risk Factors Impair Recompensation and Survival in Alcohol-associated Liver Disease.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2026). PMID: 41679525 ↗
L2OTHERCited in: Interventional and Device Therapy - [190]
Ding M, Xiao Z, Hou X et al.. “Targeting G-protein-coupled receptors and gut microbiota: Ge-Lian Qi-Shen decoction elevates GLP-1 to combat non-alcoholic fatty liver disease.” Chinese medicine (2026). PMID: 41580820 ↗
L5OTHERCited in: Interventional and Device Therapy - [191]
Ambardekar AV, Bhatt A, Hoekstra M et al.. “Gene Editing Therapy in Cardiovascular Disease: 2026 ACC Scientific Statement: A Report of the American College of Cardiology.” Journal of the American College of Cardiology (2026). PMID: 41885675 ↗
L1GUIDELINECited in: History and Evolution of Treatment - [192]
März W, Scharnagl H, Abletshauser C et al.. “Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype.” Circulation (2001). PMID: 11306521 ↗
L1RCTCited in: History and Evolution of Treatment - [193]
Lansky AJ, Pietras C, Costa RA et al.. “Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.” Circulation (2005). PMID: 15811868 ↗
L1RCTCited in: History and Evolution of Treatment - [194]
Vaduganathan M, Bhatt DL, Cryer BL et al.. “Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.” Journal of the American College of Cardiology (2016). PMID: 27012778 ↗
L1RCTCited in: History and Evolution of Treatment, Complications - [195]
Guyton JR, Brown BG, Fazio S et al.. “Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.” Journal of the American College of Cardiology (2008). PMID: 18420099 ↗
L1RCTCited in: History and Evolution of Treatment - [196]
Nappo F, Esposito K, Cioffi M et al.. “Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals.” Journal of the American College of Cardiology (2002). PMID: 11923038 ↗
L1RCTCited in: History and Evolution of Treatment - [197]
Naoumova RP, Kindler H, Leccisotti L et al.. “Pioglitazone improves myocardial blood flow and glucose utilization in nondiabetic patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled study.” Journal of the American College of Cardiology (2007). PMID: 18021872 ↗
L1RCTCited in: History and Evolution of Treatment - [198]
Herrington DM, Werbel BL, Riley WA et al.. “Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease.” Journal of the American College of Cardiology (1999). PMID: 10362210 ↗
L1RCTCited in: History and Evolution of Treatment - [199]
Blake GJ, Albert MA, Rifai N et al.. “Effect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo controlled trial.” European heart journal (2003). PMID: 14563343 ↗
L1RCTCited in: History and Evolution of Treatment - [200]
Austin MA, McKnight B, Edwards KL et al.. “Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study.” Circulation (2000). PMID: 10859281 ↗
L2COHORTCited in: History and Evolution of Treatment - [201]
Jenkins DJ, Wolever TM, Rao AV et al.. “Effect on blood lipids of very high intakes of fiber in diets low in saturated fat and cholesterol.” The New England journal of medicine (1993). PMID: 8389421 ↗
L1RCTCited in: History and Evolution of Treatment - [202]
Ridker PM, Rifai N, Clearfield M et al.. “Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.” The New England journal of medicine (2001). PMID: 11430324 ↗
L1RCTCited in: History and Evolution of Treatment - [203]
Walsh JM, Pignone M. “Drug treatment of hyperlipidemia in women.” JAMA (2004). PMID: 15138247 ↗
L1SR_OBSCited in: History and Evolution of Treatment - [204]
Szapary PO, Wolfe ML, Bloedon LT et al.. “Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial.” JAMA (2003). PMID: 12915429 ↗
L1RCTCited in: History and Evolution of Treatment - [205]
Esposito K, Giugliano F, Di Palo C et al.. “Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial.” JAMA (2004). PMID: 15213209 ↗
L1RCTCited in: History and Evolution of Treatment - [206]
Ballantyne CM, Podet EJ, Patsch WP et al.. “Effects of cyclosporine therapy on plasma lipoprotein levels.” JAMA (1989). PMID: 2733125 ↗
L2RCTCited in: History and Evolution of Treatment - [207]
Esposito K, Pontillo A, Di Palo C et al.. “Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial.” JAMA (2003). PMID: 12684358 ↗
L1RCTCited in: History and Evolution of Treatment - [208]
Jenkins DJ, Jones PJ, Lamarche B et al.. “Effect of a dietary portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia: a randomized controlled trial.” JAMA (2011). PMID: 21862744 ↗
L1RCTCited in: History and Evolution of Treatment, Prognosis and Natural History - [209]
Brass EP. “Changing the status of drugs from prescription to over-the-counter availability.” The New England journal of medicine (2001). PMID: 11556302 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [210]
Ridker PM, Hennekens CH, Rifai N et al.. “Hormone replacement therapy and increased plasma concentration of C-reactive protein.” Circulation (1999). PMID: 10449692 ↗
L4OTHERCited in: History and Evolution of Treatment - [211]
Beaumont V, Lemort N, Beaumont JL. “Oral contraceptives, sex steroid-induced antibodies and vascular thrombosis: results from 1318 cases.” European heart journal (1991). PMID: 1782953 ↗
L3OTHERCited in: History and Evolution of Treatment - [212]
Ahmad A, Khan M, Ghayyad K et al.. “Statin therapy is not associated with inferior postoperative outcomes after arthroscopic rotator cuff repair: a systematic review and meta-analysis.” Journal of shoulder and elbow surgery (2026). PMID: 42173477 ↗
L1SR_OBSCited in: History and Evolution of Treatment, Prognosis and Natural History - [213]
Jia D, Wang H, Jiang W et al.. “A novel recombinant anti-cluster of differentiation 20 humanized monoclonal antibody (B001) for the treatment of neuromyelitis optica spectrum disorder: a phase 1, multicenter randomized, double-blind trial.” Frontiers in immunology (2026). PMID: 42079612 ↗
L1RCTCited in: History and Evolution of Treatment, Complications - [214]
Song X, Hu Y, Chen Y. “Uterine fibroids detected in early pregnancy and their association with adverse pregnancy outcomes: a single-centre retrospective cohort study.” BMC pregnancy and childbirth (2026). PMID: 42026504 ↗
L4COHORTCited in: History and Evolution of Treatment, Prognosis and Natural History, Special Populations and Prevention - [215]
Fancher A, Lopez-Candales A, Sawalha K. “Statins, LDL-C and Beyond: A Contemporary Review of Atherosclerotic Cardiovascular Risk Assessment and Management.” Journal of lipid and atherosclerosis (2025). PMID: 42211141 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [216]
Wang L, Niu Y, Wang L. “Pontine infarction isolated to trigeminal sensory fibers: a case report.” Frontiers in pain research (Lausanne, Switzerland) (2026). PMID: 42317569 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment - [217]
Arias-Romero J, Mambetsariev I, Fricke J et al.. “Case report: durable response to osimertinib, radiotherapy, and chemotherapy combination in advanced non-small cell lung cancer with atypical metastasis.” Translational lung cancer research (2026). PMID: 42291351 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment - [218]
Bauer RC, Tohyama J, Cui J et al.. “Knockout of Adamts7, a novel coronary artery disease locus in humans, reduces atherosclerosis in mice.” Circulation (2015). PMID: 25712206 ↗
L5OTHERCited in: Complications - [219]
Coberly EA, Hammer RD. “Images in clinical medicine: Morphologic changes in erythrocytes in hypertriglyceridemia.” The New England journal of medicine (2014). PMID: 25119625 ↗
L4CASE_REPORTCited in: Complications - [220]
Zhang J, Hu Z, Song C et al.. “Hemoglobin glycation index correlates with the prognoses of critically ill patients with hyperlipidemia: a retrospective cohort study from the MIMIC-IV database.” BMC endocrine disorders (2026). PMID: 42168947 ↗
L4COHORTCited in: Complications, Prognosis and Natural History - [221]
Zulfa IM, Risni HW, Brauer R et al.. “Risk of adverse effects of the concomitant use of statins with calcium channel blockers: a systematic review and meta-analysis.” Postgraduate medicine (2026). PMID: 42357832 ↗
L1SR_OBSCited in: Complications - [222]
Zeng C, Lyu H, Lou L et al.. “Association between stress hyperglycemic ratio and stroke in older people with metabolic syndrome: a prospective cohort study from UK Biobank.” Frontiers in endocrinology (2026). PMID: 42051452 ↗
L2COHORTCited in: Prognosis and Natural History - [223]
Lee YJ, Lee JH, Kim M et al.. “Combined Pre-Hypertension, Pre-Diabetes, and Pre-Hyperlipidemia and Long-Term Cardiovascular Risk in Young Adults: A Nationwide Cohort Study.” European journal of preventive cardiology (2026). PMID: 42044147 ↗
L2COHORTCited in: Prognosis and Natural History - [224]
Nourollahpour Shiadeh M, Pakdaman K, Esmaeilnia Shirvani A et al.. “Global incidence and risk factors of pregnancy-related stroke: a systematic review and meta-analysis of over 270 million women.” BMC pregnancy and childbirth (2025). PMID: 41419807 ↗
L1SR_OBSCited in: Special Populations and Prevention - [225]
Yan C, Shen X, Han S et al.. “Integrated lifestyle management to mitigate MASLD risk in patients with chronic kidney disease: a prospective cohort study.” Journal of translational medicine (2026). PMID: 41782035 ↗
L2COHORTCited in: Special Populations and Prevention - [226]
Camara J, Tsujiguchi H, Hara A et al.. “Chronic pain and mortality risk among middle-age and older Japanese: the Shika town cohort study.” Pain reports (2025). PMID: 41244944 ↗
L2COHORTCited in: Special Populations and Prevention - [227]
Chen Y, Huang L, Hu T et al.. “The changing trend of hepatitis B virus carrier rate with different combinations of hepatitis B virus markers and their impact on maternal perinatal characteristics and pregnancy outcomes: a multicenter retrospective cohort study.” Virology journal (2025). PMID: 41214772 ↗
L3COHORTCited in: Special Populations and Prevention - [228]
Naim MAAZ, Sumida K, Streja E et al.. “Lipid-Lowering Therapies in Patients with Chronic Kidney Disease: A Perspective on High-Density Lipoprotein Cholesterol.” Drugs (2026). PMID: 41528633 ↗
L5REVIEW_NARRATIVECited in: Special Populations and Prevention - [229]
Hsiao PJ, Tsou LL, Yang CC et al.. “Magnesium Oxide Use and Clinical Outcomes in CKD Patients: Evidence from a Nationwide Population-Based Cohort Study in Taiwan.” International journal of medical sciences (2026). PMID: 41938509 ↗
L3COHORTCited in: Special Populations and Prevention - [230]
Delbari A, Akbarzadeh I, Bidkhori M et al.. “The Prevalence and Associated Factors of Smoking and Smoking-Cessation in Iranian Older Adults: Ardakan Cohort Study on Aging (ACSA).” Substance use & misuse (2026). PMID: 41782359 ↗
L4COHORTCited in: Special Populations and Prevention - [231]
You X, Xu Y, Zhao J et al.. “The association of geriatric nutritional risk and perioperative anesthesia-related adverse reactions in elderly patients with colorectal cancer-a prospective study.” Translational cancer research (2025). PMID: 41234882 ↗
L2COHORTCited in: Special Populations and Prevention - [232]
Huang J, Ding Z, Huang G et al.. “Clinical analysis of 48 patients with carotid web diagnosed by digital subtraction angiography.” Frontiers in neurology (2026). PMID: 42597884 ↗
L1bCited in: Definition, Classification and Nomenclature - [233]
Rayyan A, Bishev D, Bazikian Y et al.. “Comparing coronary computed tomography angiography to single-photon emission computed tomography in the evaluation of chest pain in the emergency department.” Journal of cardiovascular computed tomography (2026). PMID: 42601304 ↗
L2bCited in: Definition, Classification and Nomenclature - [234]
Zhou Y, Zhu L, An H et al.. “Independent and synergistic effects of OGTT-based hyperglycemia phenotypes and gestational weight gain on feto-maternal outcomes in GDM.” BMC pregnancy and childbirth (2026). PMID: 42157035 ↗
L2bCited in: Definition, Classification and Nomenclature - [235]
Crump C, Wei J, Sundquist J et al.. “Adverse pregnancy outcomes and long-term risk of peripheral artery disease: A cohort study.” PLoS medicine (2026). PMID: 42479723 ↗
L3bCited in: Definition, Classification and Nomenclature - [236]
Sun Z, Sun X, Cai Q et al.. “Two-cohort machine learning approach for predicting the risk of secondary hyperlipidemia in patients with depression.” Frontiers in endocrinology (2026). PMID: 42158914 ↗
L3bCited in: Definition, Classification and Nomenclature - [237]
Yang S, Huo M, Li G et al.. “Construction of a predictive model for the risk of non-alcoholic fatty liver disease in patients with sleep apnea syndrome based on multiple machine learning algorithms: a multicenter study.” BMC medical informatics and decision making (2026). PMID: 42141448 ↗
L3bCited in: Definition, Classification and Nomenclature - [238]
Chu Q, Zhang S, Zhang H et al.. “Interpretable deep learning with pharmacogenomics predicts myocardial infarction in angiotensin receptor blocker treated hypertension.” Journal of hypertension (2026). PMID: 42052888 ↗
L3bCited in: Definition, Classification and Nomenclature - [239]
Koksoy C, Browder S, Torres Ruiz I et al.. “Wound healing, wound-free period and amputation-free survival in patients with Wound, Ischemia, and foot Infection (WIfI) stage 3 and 4 disease.” Journal of vascular surgery (2026). PMID: 41967734 ↗
L4Cited in: Definition, Classification and Nomenclature - [240]
Dangpiaei S, Kamal KM, Shoair OA et al.. “Incidence of amyloid-related imaging abnormalities and health resource utilization in patients with Alzheimer disease receiving monoclonal antibody treatments: A real-world evidence study.” Journal of managed care & specialty pharmacy (2026). PMID: 41885326 ↗
L3bCited in: Definition, Classification and Nomenclature - [241]
Hong H, Chen Y, Bao J et al.. “Development and validation of a risk prediction model for diabetic peripheral neuropathic pain in type 2 diabetes: A machine learning and statistical approach.” Diabetes research and clinical practice (2026). PMID: 41875951 ↗
L3bCited in: Definition, Classification and Nomenclature - [242]
Palmisano T, Bilchick K, Guarraia D. “Hemoglobin A1c is more predictive of type 1 myocardial infarction than low-density lipoprotein or body mass index.” Nutrition, metabolism, and cardiovascular diseases : NMCD (2026). PMID: 41864779 ↗
L3bCited in: Definition, Classification and Nomenclature - [243]
Hassan MA, Mamdouh M, Ahmed FA et al.. “Association of epicardial adipose tissue thickness and left ventricular functions in children with primary dyslipidemia.” European journal of pediatrics (2026). PMID: 42095940 ↗
L3bCited in: Definition, Classification and Nomenclature - [244]
Xu W, Xu X, Zhang M et al.. “Body roundness index mediates the association between high-density lipoprotein cholesterol and diabetic retinopathy: a population-based cross-sectional study.” BMC endocrine disorders (2026). PMID: 42237292 ↗
L3bCited in: Definition, Classification and Nomenclature - [245]
Andres W, Rothstein A, Abbruzzese S et al.. “Trends in Vascular Risk Factor Control Among US Adults With Prior Stroke: 1999 to 2023.” Journal of the American Heart Association (2026). PMID: 42179268 ↗
L3bCited in: Definition, Classification and Nomenclature - [246]
Brook RD, Korzeniewski SJ, Foster B et al.. “Mobile Health Unit Outreach to Socially Disadvantaged Urban Communities Detects Uncontrolled Cardiometabolic Risk Factors.” Journal of the American Heart Association (2026). PMID: 42132204 ↗
L3bCited in: Definition, Classification and Nomenclature - [247]
Hu K, Liu T, Pan Z et al.. “Correlation between Cerebral Small Vessel Disease and Brain Artery Remodeling and Its Hemodynamic Characteristics: An Investigation Based on 4D Flow MRI.” Academic radiology (2026). PMID: 42025517 ↗
L3bCited in: Definition, Classification and Nomenclature - [248]
Zhang W, Li L, Wang Y et al.. “Mediating role of estimated glomerular filtration rate in the association between hyperlipidemia and estimated glucose disposal rate-related mortality: a study in hyperlipidemic individuals.” Nutrition, metabolism, and cardiovascular diseases : NMCD (2026). PMID: 42000252 ↗
L3bCited in: Definition, Classification and Nomenclature - [249]
Li RC, Su LC, Huang AF et al.. “Meta-analysis of factors for osteonecrosis in systemic lupus erythematosus: integration of comprehensive literatures and multicenter databases.” Frontiers in immunology (2026). PMID: 42465773 ↗
L2aCited in: Epidemiology and Risk Factors - [250]
Lin H, Zhang H, Zhang Z et al.. “Cohort profile: Guangdong Pharmaceutical University Occupational Health Cohort in Xishan Coal Electricity Group (GDPU-OHC).” Frontiers in public health (2026). PMID: 42577389 ↗
L2bCited in: Epidemiology and Risk Factors - [251]
Nakla A, Aubin PM, Ademisoye S et al.. “Smart Implantable Device Use is Associated with Decreased Post-Discharge Hospital Utilization in Total Knee Arthroplasty Patients Who Have Metabolic Syndrome: A Propensity Score-Matched Analysis.” The Journal of arthroplasty (2026). PMID: 42586280 ↗
L3bCited in: Epidemiology and Risk Factors - [252]
Liu L, Lu JA, Velasquez EE et al.. “Gestational Diabetes and Postpartum Cardiovascular, Kidney, and Metabolic Disorders.” JAMA network open (2026). PMID: 42584895 ↗
L3bCited in: Epidemiology and Risk Factors - [253]
Denic-Roberts H, McAdam J, Engel LS et al.. “Longer-term neurological and endocrine/metabolic conditions in the deepwater horizon oil spill coast guard cohort study: A principal component analysis.” International archives of occupational and environmental health (2026). PMID: 42584698 ↗
L3bCited in: Epidemiology and Risk Factors - [254]
Filippatos C, Fotiou D, Kostakou P et al.. “Real-world cardiovascular safety profile of bexarotene for the treatment of mycosis fungoides.” Clinical and experimental medicine (2026). PMID: 42576057 ↗
L3bCited in: Epidemiology and Risk Factors - [255]
Zhang C, Sandhur BS, Theotoka D et al.. “Risk of Pseudophakic Cystoid Macular Edema in Eyes With Previous Pars Plana Vitrectomy.” JAMA ophthalmology (2026). PMID: 42530955 ↗
L3bCited in: Epidemiology and Risk Factors - [256]
Luther M, Wittig T, Winther B et al.. “Five-Year Outcomes of Endovascular Aortoiliac Reconstruction in Complex Lesions: A Retrospective Single-Center Study.” Journal of clinical medicine (2026). PMID: 42513323 ↗
L4Cited in: Epidemiology and Risk Factors - [257]
Moshawih S, Gharaibeh L, Alfreahat I et al.. “Real-World Pharmacotherapy-Driven Cardiovascular Risk Prediction Using Interpretable Machine Learning and Jordanian EHR Data.” Medical sciences (Basel, Switzerland) (2026). PMID: 42506312 ↗
L3bCited in: Epidemiology and Risk Factors - [258]
Chuang YC, Wang CC, Chen IC et al.. “Cardiometabolic disease and risk of total knee arthroplasty among patients with knee osteoarthritis receiving intra-articular hyaluronic acid: a real-world cohort study.” Therapeutic advances in musculoskeletal disease (2026). PMID: 42482885 ↗
L3bCited in: Epidemiology and Risk Factors - [259]
Lee J, Kim J, Hwang J et al.. “Incidence patterns of cardiometabolic comorbidities in patients with schizophrenia: A retrospective cohort study in Korea.” Psychiatry research (2026). PMID: 42475856 ↗
L3bCited in: Epidemiology and Risk Factors - [260]
Loscocco GG, Aperna F, Iftikhar M et al.. “Cancer history and second cancer risk in polycythemia vera and essential thrombocythemia.” Blood cancer journal (2026). PMID: 42436123 ↗
L3bCited in: Epidemiology and Risk Factors - [261]
Boutros T, Ghusn W, Klim J et al.. “Beyond Initial Resolution: Predictors of Recurrence of Obesity-related Medical Conditions after Metabolic and Bariatric Surgery.” Obesity surgery (2026). PMID: 42432395 ↗
L3bCited in: Epidemiology and Risk Factors - [262]
Chuang YC, Huang YJ, Lai MC et al.. “Sex differences in 5-year incidence and prevalence of physical illnesses following early childhood autism diagnosis.” JCPP advances (2026). PMID: 42416613 ↗
L3bCited in: Epidemiology and Risk Factors - [263]
Wei L, Tao Q, You S et al.. “Chronic Pain Synergizes With High-Fat Diet to Promote Cardiac Injury via c-Jun N-Terminal Kinase 1/Silent Information Regulator 1 Signaling Axis in Apolipoprotein E-Deficient Mice.” Journal of the American Heart Association (2026). PMID: 42535523 ↗
L1bCited in: Pathophysiology and Mechanism - [264]
Wu E, Jiang J, Hasan N et al.. “Novel Systemic Associations of Idiopathic Epiretinal Membrane Identified via Machine Learning.” Ophthalmology science (2026). PMID: 41908500 ↗
L3bCited in: Pathophysiology and Mechanism - [265]
Patel H, Pathak A, Rajalekshmi R et al.. “Galectin-3, transforming growth factor beta 1, and brain natriuretic peptide in cardiac remodeling under hyperlipidemic and hyperglycemic stress.” Molecular and cellular biochemistry (2026). PMID: 42384346 ↗
L4Cited in: Pathophysiology and Mechanism - [266]
Dong M, Liu Y, Pu Z et al.. “QDPR rs3733570 polymorphism is associated with type 2 diabetes and diabetic kidney disease accompanied by hyperlipidemia in the Chinese Han population.” Frontiers in medicine (2026). PMID: 42205834 ↗
L3bCited in: Pathophysiology and Mechanism - [267]
Liu C, Zhang Q, Zhang Y. “The factors between BMI and diabetic nephropathy and protective role of the FGF21-SIRT1 axis in diabetic nephropathy.” Molecular and cellular biochemistry (2026). PMID: 42348140 ↗
L3bCited in: Pathophysiology and Mechanism - [268]
Rabadi MH, Russell KA, Xu C. “Presence and Impact of Fatigue in Patients With Multiple Sclerosis.” Medical science monitor : international medical journal of experimental and clinical research (2026). PMID: 42410895 ↗
L3bCited in: Pathophysiology and Mechanism - [269]
Xu L, Xiong X, Zhou Y et al.. “Retinal hemodynamic and caliber biomarkers for the assessment of cerebral small vessel disease burden: insights from fundus fluorescein angiography.” BMC neurology (2026). PMID: 42185800 ↗
L3bCited in: Pathophysiology and Mechanism - [270]
Yang M, Cheng X, Guan J et al.. “Diabetes Status Modifies the Association Between Carotid Plaque Burden and Retinal Microvascular Parameters.” International journal of medical sciences (2026). PMID: 42080061 ↗
L3bCited in: Pathophysiology and Mechanism - [271]
Đuran I, Ljubičić B, Joldić MN et al.. “Clinical and Echocardiographic Predictors of Major Adverse Cardiovascular Events in ANCA-Associated Vasculitis.” Medicina (Kaunas, Lithuania) (2026). PMID: 42075582 ↗
L3bCited in: Pathophysiology and Mechanism - [272]
Geng Z, He J, Zhou X et al.. “Predictive value of left ventricular global longitudinal strain for mid-term major adverse cardiovascular events in patients with atrial fibrillation complicated by acute myocardial infarction.” BMC cardiovascular disorders (2026). PMID: 41998509 ↗
L3bCited in: Pathophysiology and Mechanism - [273]
Yan C, Li S, Zhuang B et al.. “Evaluation of non-dilated left ventricular cardiomyopathy patients with reduced and preserved left ventricular ejection fraction using cardiac magnetic resonance feature tracking technology.” BMC cardiovascular disorders (2026). PMID: 41896746 ↗
L3bCited in: Pathophysiology and Mechanism - [274]
Zhang Q, Xu J, Qian Y. “Association between TyHGB and hyperuricemia and gout in patients with type-2 diabetes mellitus.” BMC endocrine disorders (2026). PMID: 42062982 ↗
L3bCited in: Clinical Presentation - [275]
Górska M, Wróbel F, Rząsa M et al.. “Prevalence and Risk Factors of Hepatic Steatosis in Kidney Transplant Recipients.” Annals of transplantation (2026). PMID: 42515854 ↗
L3bCited in: Clinical Presentation - [276]
Cook DN, Ravindran A, O'Connor S et al.. “Coronary Artery Calcium Score Predicts Cardiovascular and Transplant-Related Outcomes in Lung Transplant Recipients.” Clinical transplantation (2026). PMID: 42257486 ↗
L3bCited in: Clinical Presentation - [277]
Erinmez MA, Örs F, Yeşilova M. “Emergency Department Sudden Deafness: Clinical Features and Predictors of Advanced Imaging.” The Journal of craniofacial surgery (2026). PMID: 42090229 ↗
L3bCited in: Clinical Presentation - [278]
Zlatanović M, Živković MLJ, Zlatanović N et al.. “Foveal Density and Multi-Domain OCTA Biomarkers May Help Identify Preclinical Diabetic Microvasculopathy in Type 2 Diabetes Mellitus.” Medicina (Kaunas, Lithuania) (2026). PMID: 42356165 ↗
L3bCited in: Diagnosis and Workup - [279]
Wu M, Chen J, Lin Z et al.. “Circulating multiple metals and mortality after myocardial infarction: incremental value beyond GRACE.” American journal of preventive cardiology (2026). PMID: 42291071 ↗
L2bCited in: Severity Staging and Risk Stratification - [280]
Peng Q, Long Y, Yang K et al.. “Prognostic analysis of acute pancreatitis due to different etiologies and establishment and validation of an early prediction model.” Lipids in health and disease (2026). PMID: 41645226 ↗
L2bCited in: Severity Staging and Risk Stratification - [281]
Xu X, Sun M, Cao S et al.. “Development of a predictive model for visual outcomes and risk factors of bilateral involvement for non-arteritic anterior ischemic optic neuropathy (NAION) in Chinese patients.” Eye and vision (London, England) (2026). PMID: 42596023 ↗
L3bCited in: Severity Staging and Risk Stratification - [282]
Zhang Y, Liu G, Yu X et al.. “Metabolic Syndrome and In-Hospital Mortality in Sepsis: A Multicenter Cohort Study Revealing a Severity-Dependent Survival Advantage Driven by Overweight and Hyperlipidemia.” Shock (Augusta, Ga.) (2026). PMID: 42474243 ↗
L3bCited in: Severity Staging and Risk Stratification - [283]
Khaderi IM, Kandahari N, Saleh AW et al.. “Development of the TORS severe outcome score: a preoperative risk stratification tool for postoperative morbidity in oropharyngeal cancer.” Oral oncology (2026). PMID: 42308859 ↗
L3bCited in: Severity Staging and Risk Stratification - [284]
Cinezan C, Hiceag ML. “Self-Reported Habitual Daily Physical Activity as an Independent Predictor of Coronary Artery Disease Extension in Patients with Myocardial Infarction: A Prospective Observational Study.” Journal of clinical medicine (2026). PMID: 42194773 ↗
L3bCited in: Severity Staging and Risk Stratification - [285]
Zou XC, Xu LY, Yuan YY et al.. “Disitamab vedotin (RC48) combined with PD-1 inhibitors in locally advanced or metastatic urothelial carcinoma: clinical outcomes and prognostic factors from a multicenter real-world study.” Frontiers in immunology (2026). PMID: 42136642 ↗
L3bCited in: Severity Staging and Risk Stratification - [286]
Srikumar A, Yuvchenko O, Kang J. “Hydroxychloroquine use and 5-year cardiometabolic profile and cardiovascular risk in isolated discoid lupus erythematosus: A retrospective cohort study.” Journal of the American Academy of Dermatology (2026). PMID: 42002081 ↗
L3bCited in: Severity Staging and Risk Stratification - [287]
Thompson LL, Shah SB, Gregg AT et al.. “Cardiac risk, outcomes, and management among older adults with stage I-II non-small cell lung cancer undergoing stereotactic body radiation therapy.” Journal of geriatric oncology (2026). PMID: 41856027 ↗
L3bCited in: Severity Staging and Risk Stratification - [288]
Sen J, Salim A, Lekamlage DH et al.. “Clinical risk score for cardiac death or heart failure hospitalization in moderate aortic stenosis.” Echo research and practice (2026). PMID: 41834049 ↗
L4Cited in: Severity Staging and Risk Stratification - [289]
Chwa JS, Hong AT, Lin F et al.. “Immune checkpoint inhibitors are associated with peripheral artery disease in cancer patients.” Journal of vascular surgery (2026). PMID: 41687935 ↗
L3bCited in: Severity Staging and Risk Stratification - [290]
Micker M, Balcer-Dymel N, Pruszynska-Oszmalek E et al.. “Effect of L‑arginine supplementation on homocysteine and asymmetric dimethylarginine in atherosclerotic lower limb ischemia.” Journal of physiology and pharmacology : an official journal of the Polish Physiological Society (2026). PMID: 42533453 ↗
L1bCited in: Acute and Initial Management - [291]
Ali AH, Tak KA, Taylor-Yeremeeva EM et al.. “Mental health-related quality of life is associated with sustained lipid-lowering therapy adherence after acute coronary syndrome.” Lipids in health and disease (2026). PMID: 42482230 ↗
L3bCited in: Acute and Initial Management - [292]
Gong J, Chiu N, Clinch KA et al.. “Treatment of Cardiometabolic Risk Factors Among U.S. Adults With Cardiovascular-Kidney-Metabolic Syndrome.” Journal of the American College of Cardiology (2026). PMID: 42307495 ↗
L3bCited in: Acute and Initial Management - [293]
Yan S, Zhang F, Fang Z et al.. “Construction and validation of a diagnostic model for obstructive coronary artery disease in patients with suspected unstable angina pectoris based on resting 18F-fluorodeoxyglucose positron emission tomography myocardial ischemia memory imaging.” Quantitative imaging in medicine and surgery (2026). PMID: 42582781 ↗
L3bCited in: Acute and Initial Management - [294]
Wen Y, Chen W, Zhang W et al.. “The Correlation Analysis of C-Reactive Protein-Triglyceride-Glucose Index with the Severity of Hyperlipidemic Acute Pancreatitis.” Digestive diseases and sciences (2026). PMID: 42474624 ↗
L3bCited in: Acute and Initial Management - [295]
Ba Y, Liu B, Zhu P. “Risk stratification for stroke in acute persistent vertigo: development and internal validation of a multivariable prediction model.” Frontiers in neurology (2026). PMID: 42422204 ↗
L4Cited in: Acute and Initial Management - [296]
Pairawan S, Lee M, Shepard A et al.. “A Single-Center Experience with Paravisceral Transaortic Endarterectomy: Establishing Evidence for Efficacy and Safety in Complex Aortic Occlusive Disease.” Annals of vascular surgery (2026). PMID: 42372862 ↗
L4Cited in: Acute and Initial Management - [297]
Yuan YE, Porter LM, Haas AV et al.. “The impact of statins on aldosterone production in healthy adults: a randomized controlled study.” Journal of the Endocrine Society (2026). PMID: 42404178 ↗
L1bCited in: Long-term Guideline-Directed Therapy - [298]
Yu Z, Liu X, Wang X et al.. “Establishment of a machine learning prediction model for Wallerian degeneration after ischemic stroke.” Frontiers in medicine (2026). PMID: 42454109 ↗
L3bCited in: Long-term Guideline-Directed Therapy - [299]
Wei YF, Wang YS, Song JY et al.. “Restoration of peripheral ILC3s by washed microbiota transplantation improves lipid profiles in hyperlipidemia patients.” Frontiers in immunology (2025). PMID: 41415268 ↗
L2bCited in: Interventional and Device Therapy - [300]
Xu J, Luo D, Lei Y et al.. “Correlation between abnormal microvascular perfusion and quantitative flow ratio after primary PCI in patients with STEMI.” International journal of cardiology (2024). PMID: 39746473 ↗
L2bCited in: Interventional and Device Therapy - [301]
Gupta AR, Kumar A, Cao JJL et al.. “Preimplantation AI-ECG Age as a Predictor of Survival Following Cardiac Resynchronization Therapy.” JACC. Clinical electrophysiology (2025). PMID: 41441802 ↗
L3bCited in: Interventional and Device Therapy - [302]
Muayad J, Tukur HN, Loya A et al.. “Nationwide Analysis of Progressive Kidney Function Decline and Diabetic Macular Edema in Type 2 Diabetes.” Ophthalmology science (2025). PMID: 41216263 ↗
L3bCited in: Interventional and Device Therapy - [303]
Malmquist J, Davidge J, Bjurström K et al.. “Association between statin therapy as primary prevention and mortality in adults 50 years and older with chronic kidney disease without other indications.” Scandinavian journal of primary health care (2026). PMID: 41769754 ↗
L3bCited in: Interventional and Device Therapy - [304]
Fukae S, Kakuta Y, Matsumura S et al.. “Evaluation of everolimus pharmacokinetic monitoring based on trough concentration and area under the blood concentration time curve in kidney transplantation.” BMC nephrology (2026). PMID: 41555262 ↗
L3bCited in: Interventional and Device Therapy - [305]
Ang SP, Chia JE, Iglesias J et al.. “Trends, Clinical Characteristics, and Outcomes of Percutaneous Coronary Intervention in Liver Transplant Recipients.” Clinical transplantation (2025). PMID: 40373057 ↗
L3bCited in: Interventional and Device Therapy - [306]
Pradeep A, Faisal MS, Chen K et al.. “Impact of Glucagon-Like Peptide-1 Agonist Use on Weight Trajectory and Clinical Outcomes Following Liver Transplantation.” Transplantation proceedings (2026). PMID: 42259739 ↗
L2bCited in: Interventional and Device Therapy - [307]
Murat A, Karaca G, Bakhshaliyev N et al.. “The impact of epicardial adiposity on STEMI outcomes: Insights from a prospective cohort.” Clinical physiology and functional imaging (2025). PMID: 41121600 ↗
L2bCited in: Interventional and Device Therapy - [308]
Rossouw JE, Aragaki AK, Manson JE et al.. “Influence of Cardiometabolic Status on Cardiovascular Effects of Oral Menopausal Hormone Therapy.” Obstetrics and gynecology (2026). PMID: 42492078 ↗
L1bCited in: History and Evolution of Treatment - [309]
Liu M, Cai H, Tang C et al.. “Preoperative Shoulder Stiffness Was Accompanied by Distinct Supraspinatus Tendon Inflammatory Signatures but Not Inferior Long-term Outcomes After Rotator Cuff Repair.” Clinical orthopaedics and related research (2026). PMID: 42248213 ↗
L2bCited in: History and Evolution of Treatment - [310]
Shao K, Hu T, Yao Y et al.. “Detection rate and risk factors of carotid atherosclerotic plaque in patients with obstructive sleep apnea syndrome: A systematic review and meta-analysis.” Heart & lung : the journal of critical care (2026). PMID: 42526417 ↗
L2aCited in: History and Evolution of Treatment - [311]
Park KC, Kim HJ, Oh JS et al.. “Anatomical and Systemic Risk Factors for Recurrence in Medication-Related Osteonecrosis of the Jaw (MRONJ): A Retrospective Study of 812 Patients.” Journal of clinical medicine (2026). PMID: 42452398 ↗
L3bCited in: History and Evolution of Treatment - [312]
Muayad J, Chauhan MZ, Butt FR et al.. “Statin Intensity and the Risk of Noninfectious Uveitis.” Ophthalmology. Retina (2026). PMID: 42361978 ↗
L3bCited in: History and Evolution of Treatment - [313]
Kim DJ, Assel M, Elshafei A et al.. “Predictors of clomiphene citrate response in the treatment of men with testosterone deficiency.” The journal of sexual medicine (2026). PMID: 42251758 ↗
L3bCited in: History and Evolution of Treatment - [314]
Mendoza-Ayus S, Akkipeddi SM, Gunn K et al.. “Morphological and clinical predictors of symptomatic carotid webs: a cross-validated analysis of 124 webs.” Neuroradiology (2026). PMID: 42247135 ↗
L3bCited in: History and Evolution of Treatment - [315]
Li N, Chen M, Li S et al.. “Association between ADHD history and "Life's Crucial 9" cardiovascular risk factors in young adults.” American journal of preventive cardiology (2026). PMID: 42291048 ↗
L3bCited in: History and Evolution of Treatment - [316]
Ballantyne CM, Baass A, Rosenson RS et al.. “Use of plozasiran across a spectrum of hypertriglyceridemia: Long-term efficacy and safety data from the open-label extension period of SHASTA-2 and MUIR Trials.” American journal of preventive cardiology (2026). PMID: 42291067 ↗
L1bCited in: Complications - [317]
Li N, Tang W, Li N et al.. “Descriptive analysis of prescription interception patterns: characterizing medication safety risks in an outpatient setting.” Frontiers in pharmacology (2026). PMID: 42523996 ↗
L3bCited in: Complications - [318]
Chen HY, Falconer T, Ostropolets A et al.. “Heterogeneity of Treatment Effects Across Nine Glucose-Lowering Drug Classes in Type 2 Diabetes: Extension of the LEGEND-T2DM Network Study.” Diabetes, obesity & metabolism (2026). PMID: 42236281 ↗
L3bCited in: Complications - [319]
Schneider K, Lyon S, Jolicoeur W et al.. “Outpatient common femoral artery stenting for occlusive disease: Short-, mid-, and long-term results.” Journal of vascular surgery (2026). PMID: 42229618 ↗
L3bCited in: Complications - [320]
Wang J, Chen M, Wu H et al.. “Association of Maternal Hyperlipidemia Combined with Gestational Diabetes Mellitus with Adverse Maternal and Neonatal Outcomes: A Retrospective Cohort Study.” International journal of women's health (2026). PMID: 42438476 ↗
L4Cited in: Complications - [321]
Metlock FE, Stanislas KA, Vaidya D et al.. “Psychological Health, Polysocial Risk, and Cardiovascular Health Among Women of Reproductive Age.” JACC. Advances (2026). PMID: 42312757 ↗
L3bCited in: Complications - [322]
Rask-Andersen M, Lo Faro V, Karlsson T et al.. “Age-related changes in adiposity and cardiometabolic disease risk: a longitudinal and prospective study in the UK Biobank.” International journal of obesity (2005) (2026). PMID: 42457939 ↗
L2bCited in: Prognosis and Natural History - [323]
Burke L, Leupold O, Perez S et al.. “Fewer lifestyle-related chronic diseases and higher out-of-pocket costs are predictive of favorable response to intra-articular platelet-rich plasma injections in the treatment of knee osteoarthritis.” PM & R : the journal of injury, function, and rehabilitation (2026). PMID: 42473805 ↗
L3bCited in: Prognosis and Natural History - [324]
Yazji IH, Abbass NJ, Kaelber DC et al.. “The Impact of PCSK9 Inhibitors on Development of Retinal Vascular Occlusions.” American journal of ophthalmology (2026). PMID: 42341975 ↗
L3bCited in: Prognosis and Natural History - [325]
Doğan D, Güler E. “Association Between the CALLY Index and Carotid Artery Stenosis Severity in Patients Younger and Older than 65 Years.” Journal of clinical medicine (2026). PMID: 42279101 ↗
L3bCited in: Special Populations and Prevention - [326]
Donà C, Rettl R, Binder-Rodriguez C et al.. “Coronary Artery Disease in Cardiac Amyloidosis: Prevalence, Clinical Relevance, and Cardiac Magnetic Resonance Imaging Features.” Journal of clinical medicine (2025). PMID: 41464702 ↗
L3bCited in: Special Populations and Prevention - [327]
Quist-Nelson J, Meng ML, Rich-Edwards J et al.. “Adverse pregnancy outcomes and development of short-term cardiovascular disease risk factors.” American journal of obstetrics & gynecology MFM (2025). PMID: 41349795 ↗
L3bCited in: Special Populations and Prevention - [328]
Wu K, Lu Y, Liu A et al.. “Unconventional multi-morbidity patterns in older adults: results from 39,172 Chinese health examination population at primary healthcare centers.” BMC geriatrics (2026). PMID: 42098670 ↗
L3bCited in: Special Populations and Prevention - [329]
Bossingham J, Peng K, McKnight S et al.. “Prevalence and Correlates of Prolonged Lapses in Physician Care Among Adults with Diabetes over 4 Years: A National Study, 2018-2022.” Journal of general internal medicine (2026). PMID: 41979724 ↗
L3bCited in: Special Populations and Prevention - [330]
Li Y, Hu Q, Wang B et al.. “Prevalence and associated factors of uncorrected presbyopia among adults in cross-sectional Fujian Eye Study.” Frontiers in medicine (2026). PMID: 41836951 ↗
L4Cited in: Special Populations and Prevention - [331]
Amponsah MKD, Okoh AK, Cheffet-Walsh S et al.. “Lifestyle Habits and Structural Heart Abnormalities Among Former Athletes and Their Families: HUDDLE Subanalysis.” AJPM focus (2025). PMID: 41624228 ↗
L3bCited in: Special Populations and Prevention